{"id":445316,"date":"2026-06-15T09:25:00","date_gmt":"2026-06-15T01:25:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=445316"},"modified":"2026-06-15T09:25:00","modified_gmt":"2026-06-15T01:25:00","slug":"%e3%80%90eha2026%e3%80%91%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5%e5%a4%9a%e9%a0%85%e8%87%a8%e5%ba%8a%e6%95%b8%e6%93%9a%e4%ba%ae%e7%9b%b8%ef%bc%8c%e5%bd%b0%e9%a1%af%e8%a1%80%e6%b6%b2%e8%85%ab%e7%98%a4","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=445316","title":{"rendered":"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\">\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde<\/span><span class=\"legendSpanClass\">2026\u5e746\u670815\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u768417\u9805\u81e8\u5e8a\u9032\u5c55\u5df2\u57282026\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9805\u58c1\u5831\u5c55\u793a\u3002\u5c55\u793a\u6578\u64da\u6d89\u53ca\u516c\u53f8\u5169\u5927\u91cd\u78c5\u7522\u54c1\u2014\u2014\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b<sup>\u00ae<\/sup>\uff1b\u7814\u767c\u4ee3\u865f\uff1aHQP1351\uff09\u548c\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5<sup>\u00ae<\/sup>\uff1b\u7814\u767c\u4ee3\u865f\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73fe\u4e86\u516c\u53f8\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6df1\u539a\u4f48\u5c40\u548c\u5168\u7403\u5275\u65b0\u5be6\u529b\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">  <\/div>\n<p>\u5728\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u96d9\u6cbb\u7642\u9818\u57df\u540c\u6b65\u66f4\u65b0\u95dc\u9375\u5faa\u8b49\u6578\u64da\uff1a\u5728CML\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u91dd\u5c0d\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u5448\u73fe\u5f37\u52c1\u7684\u4e8c\u7dda\u6cbb\u7642\u6f5b\u529b\uff1b\u91dd\u5c0d\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2eTKI\u6cbb\u7642\u4e14\u6cbb\u7642\u5931\u6557\u7684CML-CP\u60a3\u8005\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u70ba\u4e00\u7a2e\u6a19\u6e96\u6cbb\u7642\uff1b\u540c\u6642\u8a72\u7522\u54c1\u91dd\u5c0d\u591a\u7ddaTKI\u8010\u85e5\u3001\u5408\u4f75\u9ad8\u5371\u57fa\u56e0\u7a81\u8b8a\u7684CML\u60a3\u8005\u7684\u81e8\u5e8a\u6578\u64da\u7a4d\u6975\u3002\u5728Ph+ ALL\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6301\u7e8c\u5c55\u73fe\u7a69\u5065\u7642\u6548\uff0c\u5176\u4e00\u7dda\u5168\u7403\u8a3b\u518a\u2162\u671f\uff08POLARIS-1\uff09\u6578\u64da\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u512a\u7570\u7684\u6df1\u5ea6\u7de9\u89e3\u7387\u8207\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u5152\u7ae5\u5fa9\u767c\/\u96e3\u6cbb\u6027Ph+ ALL\u7b49\u7d30\u5206\u4eba\u7fa4\u4e2d\uff0c\u8207\u5229\u6c99\u6258\u514b\u62c9\u7684\u7121\u5316\u7642\u806f\u5408\u65b9\u6848\u6536\u7a6b\u4eae\u773c\u81e8\u5e8a\u6578\u64da\u3002<\/p>\n<p>\u5229\u6c99\u6258\u514b\u62c9\u91dd\u5c0d\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u8a3b\u518a\u2161\u671f\u6578\u64da\u66f4\u65b0\uff0c\u901a\u904e\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u76f8\u95dc\u6027\u5206\u5c64\u5206\u6790\uff0c\u70ba\u5f8c\u7e8c\u7d30\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u85e5\u7b56\u7565\u3001\u512a\u5316\u500b\u9ad4\u5316\u7d66\u85e5\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4e5f\u70ba\u5176\u81e8\u5e8a\u50f9\u503c\u63d0\u4f9b\u4e86\u5f37\u6709\u529b\u7684\u4f50\u8b49\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u5f97\u5c55\u793a\uff0c\u9032\u4e00\u6b65\u8b49\u5be6\u4e86\u9019\u5169\u6b3e\u91cd\u78c5\u7522\u54c1\u5728\u5168\u7403\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6cbb\u7642\u50f9\u503c\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7642\u8def\u5f91\uff0c\u4e5f\u70baPh+ ALL\u60a3\u8005\u6cbb\u7642\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u8a3b\u518aII\u671f\u7684\u6578\u64da\u66f4\u65b0\u70ba\u4e0d\u540c\u4eba\u7fa4\u7684\u500b\u9ad4\u5316\u7528\u85e5\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\uff0c\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4f7f\u6211\u5011\u5c0d\u5176\u5728\u9019\u985e\u60a3\u8005\u7684\u61c9\u7528\u5145\u6eff\u4fe1\u5fc3\u3002\u7279\u5225\u662f\u5169\u500b\u7522\u54c1\u7684\u806f\u7528\u6578\u64da\u5448\u73fe\u7684\u5f37\u52c1\u6f5b\u529b\u8b93\u6211\u5011\u500d\u611f\u8208\u596e\u3002\u672a\u4f86\uff0c\u6211\u5011\u5c07\u7e7c\u7e8c\u52a0\u901f\u63a8\u9032\u5169\u500b\u91cd\u78c5\u7522\u54c1\u7684\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u540c\u6642\u7a4d\u6975\u63a2\u7d22\u66f4\u591a\u5275\u65b0\u806f\u5408\u6cbb\u7642\u65b9\u6848\uff0c\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u8b8a\u9769\u610f\u7fa9\u7684\u6cbb\u7642\u9078\u64c7\u3002\u300d<\/p>\n<p>\u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u7cbe\u9078\u58c1\u5831\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u76f8\u95dc\u7814\u7a76\u6578\u64da\u8acb\u67e5\u8a62EHA\u5b98\u7db2\uff09\uff1a<\/p>\n<p><b>UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)<\/b><\/p>\n<p><b>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08<\/b><b>HQP1351<\/b><b>\uff09\u4f5c\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08<\/b><b>CP-CML<\/b><b>\uff09\u4e8c\u7dda\u6cbb\u7642\u7684\u6700\u65b0\u7642\u6548\u8207\u5b89\u5168\u6027<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1aEHA-3388 (PS1733)<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1<\/li>\n<li>\u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7684II\u671f\u7814\u7a76\uff0c\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u905476.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u905447.6%\uff0c\u4e14\u53cd\u61c9\u7387\u96a8\u6cbb\u7642\u9031\u671f\u905e\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u70ba\u9019\u985e\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7dda\u6cbb\u7642\u9078\u64c7\u3002<\/li>\n<\/ul>\n<p><b>EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND <\/b><b><i>ASXL1<\/i><\/b><b> MUTATIONS<\/b><\/p>\n<p><b>\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c<\/b><b>\/<\/b><b>\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36<\/b><b><i>ASXL1<\/i><\/b><b>\u57fa\u56e0\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08<\/b><b>CP-CML<\/b><b>\uff09\u60a3\u8005\u7684\u7642\u6548<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1aEHA-3991 (PS1727)<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1<\/li>\n<li>\u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805Ib\u671f\u7814\u7a76\uff0c\u5c0d22\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u7684CP-CML\u60a3\u8005\u9032\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u8b8a\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\/22\uff09\u7684\u60a3\u8005\u651c\u5e36<i>ASXL1<\/i>\u7a81\u8b8a\u3002\u7d93\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5f8c\uff0c44.4%\uff084\/9\uff09\u7684<i>ASXL1<\/i>\u7a81\u8b8a\u60a3\u8005\u7372\u5f97\u81e8\u5e8a\u53cd\u61c9\uff0c\u5176\u4e2d22.2%\uff082\/9\uff09\u9054\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u9054\u5230MR4.5\uff09\u3002\u8a72\u7814\u7a76\u9996\u6b21\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36<i>ASXL1<\/i>\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u70ba\u591a\u91cdTKI\u8010\u85e5\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002<\/li>\n<\/ul>\n<p><b>THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL<\/b><\/p>\n<p><b>\u7d93\u81f3\u5c11\u5169\u7a2e\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f49\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u6216\u7e7c\u7e8c\u539f<\/b><b>TKI<\/b><b>\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5c0d\u7167\u7814\u7a76<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1aEHA-4595 (PS1728)<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u91ab\u9662<\/li>\n<li>\u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5c0d\u7167\u8a66\u9a57\uff0c\u7d0d\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u7a2eTKI\u6cbb\u7642\u226518\u500b\u6708\u4f46\u672a\u9054MMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7d44\u3002\u7d50\u679c\u986f\u793a\uff0c6\u500b\u6708\u6642\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44MMR\u7387\u986f\u8457\u9ad8\u65bc\u5c0d\u7167\u7d44\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u500b\u6708\u6642\u7d2f\u7a4dMMR\u7387\u5206\u5225\u70ba57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u898b3-4\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.86%\uff09\u548c\u8ca7\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b78\u4e8b\u4ef6\u7f55\u898b\u300278.57%\u7684\u60a3\u8005\u5728\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u5f8c\uff0c\u65e2\u5f80TKI\u76f8\u95dcAE\u5f97\u5230\u6539\u5584\u3002\u7d50\u8ad6\u652f\u6301\u5967\u96f7\u5df4\u66ff\u5c3c\u4f5c\u70ba\u22652\u7a2eTKI\u6cbb\u7642\u5931\u6557CML-CP\u60a3\u8005\u7684\u6f5b\u5728\u6a19\u6e96\u6cbb\u7642\u3002<\/li>\n<\/ul>\n<p><b>UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL<\/b><\/p>\n<p><b>POLARIS-1<\/b><b>\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08<\/b><b>Ph+ ALL<\/b><b>\uff09\u7684\u5168\u7403\u8a3b\u518a<\/b><b>III<\/b><b>\u671f\u81e8\u5e8a\u7814\u7a76<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1aEHA-3437 (PS1479)<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1a\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662<\/li>\n<li>\u9019\u662f\u4e00\u9805\u5168\u7403\u591a\u4e2d\u5fc3\u8a3b\u518a\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u7528\u65bc\u65b0\u8a3a\u65b7Ph+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u5165\u7d4455\u4f8b\u60a3\u8005\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642CR\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff09\u9670\u6027CR\u738763.0%\uff1b MRD\u9670\u6027\u7387\u96a8\u6cbb\u7642\u9031\u671f\u63a8\u9032\u6301\u7e8c\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7642\u9031\u671f\u672b\u905493.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u820740mg\u5291\u91cf\u7d44\u7642\u6548\u8207\u5b89\u5168\u6027\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e14\u5c0d<i>IKZF1<\/i><i><sup>plus<\/sup><\/i>\u7b49\u4e0d\u826f\u9810\u5f8c\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6a23\u9ad8\u6548\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u53ef\u70ba\u65b0\u8a3a\u65b7Ph+ ALL\u60a3\u8005\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f49\u9670\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u70baPh+ ALL\u4e00\u7dda\u6cbb\u7642\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u64da\u3002<\/li>\n<\/ul>\n<p><b>SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\/REFRACTORY (R\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY<\/b><\/p>\n<p><b>\u4e00\u9805<\/b><b>1B<\/b><b>\u671f\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\uff08<\/b><b>HQP1351<\/b><b>\uff09\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08<\/b><b>APG-2575<\/b><b>\uff09\u6cbb\u7642\u5fa9\u767c<\/b><b>\/<\/b><b>\u96e3\u6cbb\u6027\uff08<\/b><b>R\/R<\/b><b>\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08<\/b><b>Ph+ ALL<\/b><b>\uff09\u5152\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u8207\u521d\u6b65\u7642\u6548<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1aEHA-4691 (PS1473)<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\uff08\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u5b78\u7814\u7a76\u6240\uff09<\/li>\n<li>\u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u5291\u91cf\u905e\u589eIb\u671f\u7814\u7a76\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642\u65e2\u5f80\u22651\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u5152\u7ae5R\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7d4417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f6113\u6b72\uff0c40%\u651c\u5e36<i>ABL1<\/i>\u7a81\u8b8a\uff08\u542b<i>T315I<\/i>\uff09\u30029\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u806f\u5408\u6cbb\u7642\u5f8cORR\u9ad8\u905488.9%\uff0cMRD\u9670\u6027\u7387\u905466.7%\uff088\/12\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u5152\uff0814\/15\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\u7372\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7de9\u89e3\uff1b\u5169\u85e5\u5747\u53ef\u900f\u904e\u8840\u8166\u5c4f\u969c\uff0c\u5c0d<i>ABL1<\/i>\u7a81\u8b8a\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u8a72\u7121\u5316\u7642\u53e3\u670d\u96d9\u9776\u5411\u65b9\u6848\u53ef\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u7de9\u89e3\uff0c\u70ba\u5152\u7ae5R\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7642\u9078\u64c7\u3002<\/li>\n<\/ul>\n<p><b>REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY<\/b><\/p>\n<p><b>\u4e00\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u65bc\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1aEHA-5454 (PF562)<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662<\/li>\n<li>\u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u570b\u5167\u591a\u4e2d\u5fc3\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff08\u56de\u9867\u6027\uff09\uff0c\u65e8\u5728\u8a55\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u7d0d\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f61\u70ba63\u6b72\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\/CRi\u9ad8\u905472%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7d44\u7642\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u9054\u5230CR\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9670\u6027\u7387\u905461%\u3002NPM1\u7a81\u8b8a\u60a3\u8005CR\/CRi\u7387\u70ba100%\uff0cIDH2 \u7a81\u8b8a\u60a3\u8005\u70ba83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u9054\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7d1a\u6cbb\u7642\u671f\u9593\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u70ba\u8840\u7d30\u80de\u6e1b\u5c11\uff08\u8840\u5c0f\u677f\u6e1b\u5c1127%\uff0c\u8ca7\u884023%\uff0c\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1120%\uff09\uff0c\u6574\u9ad4\u53ef\u63a7\u3002\u8a72\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u6cbb\u7642\u9ad3\u7cfb\u816b\u7624\uff08\u7279\u5225\u662fAML\uff09\u5177\u6709\u512a\u7570\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002<\/li>\n<\/ul>\n<p><b>CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY<\/b><\/p>\n<p><b>\u4e00\u9805\u95dc\u9375<\/b><b>II<\/b><b>\u671f\u81e8\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08<\/b><b>APG-2575<\/b><b>\uff09\u6cbb\u7642\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5<\/b><b>\/<\/b><b>\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08<\/b><b>CLL\/SLL<\/b><b>\uff09\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u76f8\u95dc\u6027<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\u7de8\u865f\uff1aEHA-3984 (PS1713)<\/li>\n<li>\u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6a39\u6559\u6388\uff0c\u6cb3\u5357\u7701\u816b\u7624\u91ab\u9662<\/li>\n<li>\u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u57fa\u65bc\u95dc\u9375II\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u95dc\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642R\/R CLL\/SLL\u60a3\u8005\u6642\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\u7814\u7a76\u7d0d\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7642\u3002\u572872\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u70ba23.9\u500b\u6708\uff0cIRC\u8a55\u4f30ORR\u70ba62.5%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0cTP53\u7a81\u8b8a\/del(17p)\u3001\u8907\u96dc\u6838\u578b\u3001\u57fa\u6578\u8f03\u5927\u7684\u816b\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u8b8a\u8207\u8f03\u5dee\u9810\u5f8c\u76f8\u95dc\uff0c\u5176\u4e2d\u8907\u96dc\u6838\u578b\u548c\u816b\u7624\u5927\u5c0f\u662fPFS\u7e2e\u77ed\u7684\u7368\u7acb\u98a8\u96aa\u56e0\u7d20\u3002\u8a72\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7642\u5931\u6557\u5f8c\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u78ba\u7642\u6548\uff0c\u4e26\u53ef\u901a\u904e\u57fa\u7dda\u98a8\u96aa\u7279\u5fb5\u9032\u4e00\u6b65\u8b58\u5225\u9810\u5f8c\u8f03\u5dee\u4eba\u7fa4\uff0c\u70ba\u5f8c\u7e8c\u98a8\u96aa\u5206\u5c64\u548c\u806f\u5408\u6cbb\u7642\u7b56\u7565\u63d0\u4f9b\u4f9d\u64da\u3002<\/li>\n<\/ul>\n<p><b>\u95dc\u65bc\u4e9e\u76db\u91ab\u85e5<\/b><\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002<\/p>\n<p>\u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b<sup>\u00ae<\/sup>\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b<sup>\u00ae<\/sup>\u4e09\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b<sup>\u00ae<\/sup>\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b<sup>\u00ae<\/sup>\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b<sup>\u00ae<\/sup>\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002<\/p>\n<p>\u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5<sup>\u00ae<\/sup>\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5<sup>\u00ae<\/sup>\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5<sup>\u00ae<\/sup>\u56db\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5<sup>\u00ae<\/sup>\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5<sup>\u00ae<\/sup>\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5<sup>\u00ae<\/sup>\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5<sup>\u00ae<\/sup>\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002<\/p>\n<p>\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u4fc2\u3002\u5982\u9700\u77ad\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0<a href=\"https:\/\/ascentage.com\/\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/ascentage.com\/<\/a><\/p>\n<p><b>\u524d\u77bb\u6027\u8072\u660e<\/b><\/p>\n<p>\u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002<\/p>\n<p>\u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u5831\u544a\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002<\/p>\n<p>\u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607&#8230;<\/p>\n","protected":false},"author":16,"featured_media":445317,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-445316","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u768417\u9805\u81e8\u5e8a\u9032\u5c55\u5df2\u57282026\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9805\u58c1\u5831\u5c55\u793a\u3002\u5c55\u793a\u6578\u64da\u6d89\u53ca\u516c\u53f8\u5169\u5927\u91cd\u78c5\u7522\u54c1\u2014\u2014\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aHQP1351\uff09\u548c\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73fe\u4e86\u516c\u53f8\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6df1\u539a\u4f48\u5c40\u548c\u5168\u7403\u5275\u65b0\u5be6\u529b\u3002   \u5728\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u96d9\u6cbb\u7642\u9818\u57df\u540c\u6b65\u66f4\u65b0\u95dc\u9375\u5faa\u8b49\u6578\u64da\uff1a\u5728CML\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u91dd\u5c0d\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u5448\u73fe\u5f37\u52c1\u7684\u4e8c\u7dda\u6cbb\u7642\u6f5b\u529b\uff1b\u91dd\u5c0d\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2eTKI\u6cbb\u7642\u4e14\u6cbb\u7642\u5931\u6557\u7684CML-CP\u60a3\u8005\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u70ba\u4e00\u7a2e\u6a19\u6e96\u6cbb\u7642\uff1b\u540c\u6642\u8a72\u7522\u54c1\u91dd\u5c0d\u591a\u7ddaTKI\u8010\u85e5\u3001\u5408\u4f75\u9ad8\u5371\u57fa\u56e0\u7a81\u8b8a\u7684CML\u60a3\u8005\u7684\u81e8\u5e8a\u6578\u64da\u7a4d\u6975\u3002\u5728Ph+ ALL\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6301\u7e8c\u5c55\u73fe\u7a69\u5065\u7642\u6548\uff0c\u5176\u4e00\u7dda\u5168\u7403\u8a3b\u518a\u2162\u671f\uff08POLARIS-1\uff09\u6578\u64da\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u512a\u7570\u7684\u6df1\u5ea6\u7de9\u89e3\u7387\u8207\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u5152\u7ae5\u5fa9\u767c\/\u96e3\u6cbb\u6027Ph+ ALL\u7b49\u7d30\u5206\u4eba\u7fa4\u4e2d\uff0c\u8207\u5229\u6c99\u6258\u514b\u62c9\u7684\u7121\u5316\u7642\u806f\u5408\u65b9\u6848\u6536\u7a6b\u4eae\u773c\u81e8\u5e8a\u6578\u64da\u3002 \u5229\u6c99\u6258\u514b\u62c9\u91dd\u5c0d\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u8a3b\u518a\u2161\u671f\u6578\u64da\u66f4\u65b0\uff0c\u901a\u904e\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u76f8\u95dc\u6027\u5206\u5c64\u5206\u6790\uff0c\u70ba\u5f8c\u7e8c\u7d30\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u85e5\u7b56\u7565\u3001\u512a\u5316\u500b\u9ad4\u5316\u7d66\u85e5\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4e5f\u70ba\u5176\u81e8\u5e8a\u50f9\u503c\u63d0\u4f9b\u4e86\u5f37\u6709\u529b\u7684\u4f50\u8b49\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u5f97\u5c55\u793a\uff0c\u9032\u4e00\u6b65\u8b49\u5be6\u4e86\u9019\u5169\u6b3e\u91cd\u78c5\u7522\u54c1\u5728\u5168\u7403\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6cbb\u7642\u50f9\u503c\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7642\u8def\u5f91\uff0c\u4e5f\u70baPh+ ALL\u60a3\u8005\u6cbb\u7642\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u8a3b\u518aII\u671f\u7684\u6578\u64da\u66f4\u65b0\u70ba\u4e0d\u540c\u4eba\u7fa4\u7684\u500b\u9ad4\u5316\u7528\u85e5\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\uff0c\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4f7f\u6211\u5011\u5c0d\u5176\u5728\u9019\u985e\u60a3\u8005\u7684\u61c9\u7528\u5145\u6eff\u4fe1\u5fc3\u3002\u7279\u5225\u662f\u5169\u500b\u7522\u54c1\u7684\u806f\u7528\u6578\u64da\u5448\u73fe\u7684\u5f37\u52c1\u6f5b\u529b\u8b93\u6211\u5011\u500d\u611f\u8208\u596e\u3002\u672a\u4f86\uff0c\u6211\u5011\u5c07\u7e7c\u7e8c\u52a0\u901f\u63a8\u9032\u5169\u500b\u91cd\u78c5\u7522\u54c1\u7684\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u540c\u6642\u7a4d\u6975\u63a2\u7d22\u66f4\u591a\u5275\u65b0\u806f\u5408\u6cbb\u7642\u65b9\u6848\uff0c\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u8b8a\u9769\u610f\u7fa9\u7684\u6cbb\u7642\u9078\u64c7\u3002\u300d \u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u7cbe\u9078\u58c1\u5831\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u76f8\u95dc\u7814\u7a76\u6578\u64da\u8acb\u67e5\u8a62EHA\u5b98\u7db2\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7dda\u6cbb\u7642\u7684\u6700\u65b0\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3388 (PS1733)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7684II\u671f\u7814\u7a76\uff0c\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u905476.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u905447.6%\uff0c\u4e14\u53cd\u61c9\u7387\u96a8\u6cbb\u7642\u9031\u671f\u905e\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u70ba\u9019\u985e\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7dda\u6cbb\u7642\u9078\u64c7\u3002  EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u57fa\u56e0\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-3991 (PS1727)  \u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805Ib\u671f\u7814\u7a76\uff0c\u5c0d22\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u7684CP-CML\u60a3\u8005\u9032\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u8b8a\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\/22\uff09\u7684\u60a3\u8005\u651c\u5e36ASXL1\u7a81\u8b8a\u3002\u7d93\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5f8c\uff0c44.4%\uff084\/9\uff09\u7684ASXL1\u7a81\u8b8a\u60a3\u8005\u7372\u5f97\u81e8\u5e8a\u53cd\u61c9\uff0c\u5176\u4e2d22.2%\uff082\/9\uff09\u9054\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u9054\u5230MR4.5\uff09\u3002\u8a72\u7814\u7a76\u9996\u6b21\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u70ba\u591a\u91cdTKI\u8010\u85e5\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002  THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL \u7d93\u81f3\u5c11\u5169\u7a2e\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f49\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5c0d\u7167\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-4595 (PS1728)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5c0d\u7167\u8a66\u9a57\uff0c\u7d0d\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u7a2eTKI\u6cbb\u7642\u226518\u500b\u6708\u4f46\u672a\u9054MMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7d44\u3002\u7d50\u679c\u986f\u793a\uff0c6\u500b\u6708\u6642\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44MMR\u7387\u986f\u8457\u9ad8\u65bc\u5c0d\u7167\u7d44\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u500b\u6708\u6642\u7d2f\u7a4dMMR\u7387\u5206\u5225\u70ba57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u898b3-4\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.86%\uff09\u548c\u8ca7\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b78\u4e8b\u4ef6\u7f55\u898b\u300278.57%\u7684\u60a3\u8005\u5728\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u5f8c\uff0c\u65e2\u5f80TKI\u76f8\u95dcAE\u5f97\u5230\u6539\u5584\u3002\u7d50\u8ad6\u652f\u6301\u5967\u96f7\u5df4\u66ff\u5c3c\u4f5c\u70ba\u22652\u7a2eTKI\u6cbb\u7642\u5931\u6557CML-CP\u60a3\u8005\u7684\u6f5b\u5728\u6a19\u6e96\u6cbb\u7642\u3002  UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL POLARIS-1\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-3437 (PS1479)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662  \u9019\u662f\u4e00\u9805\u5168\u7403\u591a\u4e2d\u5fc3\u8a3b\u518a\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u7528\u65bc\u65b0\u8a3a\u65b7Ph+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u5165\u7d4455\u4f8b\u60a3\u8005\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642CR\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff09\u9670\u6027CR\u738763.0%\uff1b MRD\u9670\u6027\u7387\u96a8\u6cbb\u7642\u9031\u671f\u63a8\u9032\u6301\u7e8c\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7642\u9031\u671f\u672b\u905493.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u820740mg\u5291\u91cf\u7d44\u7642\u6548\u8207\u5b89\u5168\u6027\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e14\u5c0dIKZF1plus\u7b49\u4e0d\u826f\u9810\u5f8c\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6a23\u9ad8\u6548\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u53ef\u70ba\u65b0\u8a3a\u65b7Ph+ ALL\u60a3\u8005\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f49\u9670\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u70baPh+ ALL\u4e00\u7dda\u6cbb\u7642\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u64da\u3002  SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\/REFRACTORY (R\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY \u4e00\u98051B\u671f\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\uff08R\/R\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u5152\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u8207\u521d\u6b65\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-4691 (PS1473)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\uff08\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u5b78\u7814\u7a76\u6240\uff09  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u5291\u91cf\u905e\u589eIb\u671f\u7814\u7a76\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642\u65e2\u5f80\u22651\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u5152\u7ae5R\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7d4417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f6113\u6b72\uff0c40%\u651c\u5e36ABL1\u7a81\u8b8a\uff08\u542bT315I\uff09\u30029\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u806f\u5408\u6cbb\u7642\u5f8cORR\u9ad8\u905488.9%\uff0cMRD\u9670\u6027\u7387\u905466.7%\uff088\/12\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u5152\uff0814\/15\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\u7372\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7de9\u89e3\uff1b\u5169\u85e5\u5747\u53ef\u900f\u904e\u8840\u8166\u5c4f\u969c\uff0c\u5c0dABL1\u7a81\u8b8a\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u8a72\u7121\u5316\u7642\u53e3\u670d\u96d9\u9776\u5411\u65b9\u6848\u53ef\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u7de9\u89e3\uff0c\u70ba\u5152\u7ae5R\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7642\u9078\u64c7\u3002  REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY \u4e00\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u65bc\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-5454 (PF562)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u570b\u5167\u591a\u4e2d\u5fc3\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff08\u56de\u9867\u6027\uff09\uff0c\u65e8\u5728\u8a55\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u7d0d\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f61\u70ba63\u6b72\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\/CRi\u9ad8\u905472%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7d44\u7642\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u9054\u5230CR\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9670\u6027\u7387\u905461%\u3002NPM1\u7a81\u8b8a\u60a3\u8005CR\/CRi\u7387\u70ba100%\uff0cIDH2 \u7a81\u8b8a\u60a3\u8005\u70ba83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u9054\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7d1a\u6cbb\u7642\u671f\u9593\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u70ba\u8840\u7d30\u80de\u6e1b\u5c11\uff08\u8840\u5c0f\u677f\u6e1b\u5c1127%\uff0c\u8ca7\u884023%\uff0c\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1120%\uff09\uff0c\u6574\u9ad4\u53ef\u63a7\u3002\u8a72\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u6cbb\u7642\u9ad3\u7cfb\u816b\u7624\uff08\u7279\u5225\u662fAML\uff09\u5177\u6709\u512a\u7570\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002  CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY \u4e00\u9805\u95dc\u9375II\u671f\u81e8\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u76f8\u95dc\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3984 (PS1713)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6a39\u6559\u6388\uff0c\u6cb3\u5357\u7701\u816b\u7624\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u57fa\u65bc\u95dc\u9375II\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u95dc\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642R\/R CLL\/SLL\u60a3\u8005\u6642\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\u7814\u7a76\u7d0d\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7642\u3002\u572872\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u70ba23.9\u500b\u6708\uff0cIRC\u8a55\u4f30ORR\u70ba62.5%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0cTP53\u7a81\u8b8a\/del(17p)\u3001\u8907\u96dc\u6838\u578b\u3001\u57fa\u6578\u8f03\u5927\u7684\u816b\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u8b8a\u8207\u8f03\u5dee\u9810\u5f8c\u76f8\u95dc\uff0c\u5176\u4e2d\u8907\u96dc\u6838\u578b\u548c\u816b\u7624\u5927\u5c0f\u662fPFS\u7e2e\u77ed\u7684\u7368\u7acb\u98a8\u96aa\u56e0\u7d20\u3002\u8a72\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7642\u5931\u6557\u5f8c\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u78ba\u7642\u6548\uff0c\u4e26\u53ef\u901a\u904e\u57fa\u7dda\u98a8\u96aa\u7279\u5fb5\u9032\u4e00\u6b65\u8b58\u5225\u9810\u5f8c\u8f03\u5dee\u4eba\u7fa4\uff0c\u70ba\u5f8c\u7e8c\u98a8\u96aa\u5206\u5c64\u548c\u806f\u5408\u6cbb\u7642\u7b56\u7565\u63d0\u4f9b\u4f9d\u64da\u3002  \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u4fc2\u3002\u5982\u9700\u77ad\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u5831\u544a\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=445316\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u768417\u9805\u81e8\u5e8a\u9032\u5c55\u5df2\u57282026\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9805\u58c1\u5831\u5c55\u793a\u3002\u5c55\u793a\u6578\u64da\u6d89\u53ca\u516c\u53f8\u5169\u5927\u91cd\u78c5\u7522\u54c1\u2014\u2014\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aHQP1351\uff09\u548c\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73fe\u4e86\u516c\u53f8\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6df1\u539a\u4f48\u5c40\u548c\u5168\u7403\u5275\u65b0\u5be6\u529b\u3002   \u5728\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u96d9\u6cbb\u7642\u9818\u57df\u540c\u6b65\u66f4\u65b0\u95dc\u9375\u5faa\u8b49\u6578\u64da\uff1a\u5728CML\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u91dd\u5c0d\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u5448\u73fe\u5f37\u52c1\u7684\u4e8c\u7dda\u6cbb\u7642\u6f5b\u529b\uff1b\u91dd\u5c0d\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2eTKI\u6cbb\u7642\u4e14\u6cbb\u7642\u5931\u6557\u7684CML-CP\u60a3\u8005\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u70ba\u4e00\u7a2e\u6a19\u6e96\u6cbb\u7642\uff1b\u540c\u6642\u8a72\u7522\u54c1\u91dd\u5c0d\u591a\u7ddaTKI\u8010\u85e5\u3001\u5408\u4f75\u9ad8\u5371\u57fa\u56e0\u7a81\u8b8a\u7684CML\u60a3\u8005\u7684\u81e8\u5e8a\u6578\u64da\u7a4d\u6975\u3002\u5728Ph+ ALL\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6301\u7e8c\u5c55\u73fe\u7a69\u5065\u7642\u6548\uff0c\u5176\u4e00\u7dda\u5168\u7403\u8a3b\u518a\u2162\u671f\uff08POLARIS-1\uff09\u6578\u64da\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u512a\u7570\u7684\u6df1\u5ea6\u7de9\u89e3\u7387\u8207\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u5152\u7ae5\u5fa9\u767c\/\u96e3\u6cbb\u6027Ph+ ALL\u7b49\u7d30\u5206\u4eba\u7fa4\u4e2d\uff0c\u8207\u5229\u6c99\u6258\u514b\u62c9\u7684\u7121\u5316\u7642\u806f\u5408\u65b9\u6848\u6536\u7a6b\u4eae\u773c\u81e8\u5e8a\u6578\u64da\u3002 \u5229\u6c99\u6258\u514b\u62c9\u91dd\u5c0d\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u8a3b\u518a\u2161\u671f\u6578\u64da\u66f4\u65b0\uff0c\u901a\u904e\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u76f8\u95dc\u6027\u5206\u5c64\u5206\u6790\uff0c\u70ba\u5f8c\u7e8c\u7d30\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u85e5\u7b56\u7565\u3001\u512a\u5316\u500b\u9ad4\u5316\u7d66\u85e5\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4e5f\u70ba\u5176\u81e8\u5e8a\u50f9\u503c\u63d0\u4f9b\u4e86\u5f37\u6709\u529b\u7684\u4f50\u8b49\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u5f97\u5c55\u793a\uff0c\u9032\u4e00\u6b65\u8b49\u5be6\u4e86\u9019\u5169\u6b3e\u91cd\u78c5\u7522\u54c1\u5728\u5168\u7403\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6cbb\u7642\u50f9\u503c\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7642\u8def\u5f91\uff0c\u4e5f\u70baPh+ ALL\u60a3\u8005\u6cbb\u7642\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u8a3b\u518aII\u671f\u7684\u6578\u64da\u66f4\u65b0\u70ba\u4e0d\u540c\u4eba\u7fa4\u7684\u500b\u9ad4\u5316\u7528\u85e5\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\uff0c\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4f7f\u6211\u5011\u5c0d\u5176\u5728\u9019\u985e\u60a3\u8005\u7684\u61c9\u7528\u5145\u6eff\u4fe1\u5fc3\u3002\u7279\u5225\u662f\u5169\u500b\u7522\u54c1\u7684\u806f\u7528\u6578\u64da\u5448\u73fe\u7684\u5f37\u52c1\u6f5b\u529b\u8b93\u6211\u5011\u500d\u611f\u8208\u596e\u3002\u672a\u4f86\uff0c\u6211\u5011\u5c07\u7e7c\u7e8c\u52a0\u901f\u63a8\u9032\u5169\u500b\u91cd\u78c5\u7522\u54c1\u7684\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u540c\u6642\u7a4d\u6975\u63a2\u7d22\u66f4\u591a\u5275\u65b0\u806f\u5408\u6cbb\u7642\u65b9\u6848\uff0c\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u8b8a\u9769\u610f\u7fa9\u7684\u6cbb\u7642\u9078\u64c7\u3002\u300d \u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u7cbe\u9078\u58c1\u5831\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u76f8\u95dc\u7814\u7a76\u6578\u64da\u8acb\u67e5\u8a62EHA\u5b98\u7db2\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7dda\u6cbb\u7642\u7684\u6700\u65b0\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3388 (PS1733)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7684II\u671f\u7814\u7a76\uff0c\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u905476.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u905447.6%\uff0c\u4e14\u53cd\u61c9\u7387\u96a8\u6cbb\u7642\u9031\u671f\u905e\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u70ba\u9019\u985e\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7dda\u6cbb\u7642\u9078\u64c7\u3002  EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u57fa\u56e0\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-3991 (PS1727)  \u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805Ib\u671f\u7814\u7a76\uff0c\u5c0d22\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u7684CP-CML\u60a3\u8005\u9032\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u8b8a\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\/22\uff09\u7684\u60a3\u8005\u651c\u5e36ASXL1\u7a81\u8b8a\u3002\u7d93\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5f8c\uff0c44.4%\uff084\/9\uff09\u7684ASXL1\u7a81\u8b8a\u60a3\u8005\u7372\u5f97\u81e8\u5e8a\u53cd\u61c9\uff0c\u5176\u4e2d22.2%\uff082\/9\uff09\u9054\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u9054\u5230MR4.5\uff09\u3002\u8a72\u7814\u7a76\u9996\u6b21\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u70ba\u591a\u91cdTKI\u8010\u85e5\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002  THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL \u7d93\u81f3\u5c11\u5169\u7a2e\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f49\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5c0d\u7167\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-4595 (PS1728)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5c0d\u7167\u8a66\u9a57\uff0c\u7d0d\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u7a2eTKI\u6cbb\u7642\u226518\u500b\u6708\u4f46\u672a\u9054MMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7d44\u3002\u7d50\u679c\u986f\u793a\uff0c6\u500b\u6708\u6642\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44MMR\u7387\u986f\u8457\u9ad8\u65bc\u5c0d\u7167\u7d44\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u500b\u6708\u6642\u7d2f\u7a4dMMR\u7387\u5206\u5225\u70ba57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u898b3-4\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.86%\uff09\u548c\u8ca7\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b78\u4e8b\u4ef6\u7f55\u898b\u300278.57%\u7684\u60a3\u8005\u5728\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u5f8c\uff0c\u65e2\u5f80TKI\u76f8\u95dcAE\u5f97\u5230\u6539\u5584\u3002\u7d50\u8ad6\u652f\u6301\u5967\u96f7\u5df4\u66ff\u5c3c\u4f5c\u70ba\u22652\u7a2eTKI\u6cbb\u7642\u5931\u6557CML-CP\u60a3\u8005\u7684\u6f5b\u5728\u6a19\u6e96\u6cbb\u7642\u3002  UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL POLARIS-1\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-3437 (PS1479)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662  \u9019\u662f\u4e00\u9805\u5168\u7403\u591a\u4e2d\u5fc3\u8a3b\u518a\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u7528\u65bc\u65b0\u8a3a\u65b7Ph+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u5165\u7d4455\u4f8b\u60a3\u8005\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642CR\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff09\u9670\u6027CR\u738763.0%\uff1b MRD\u9670\u6027\u7387\u96a8\u6cbb\u7642\u9031\u671f\u63a8\u9032\u6301\u7e8c\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7642\u9031\u671f\u672b\u905493.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u820740mg\u5291\u91cf\u7d44\u7642\u6548\u8207\u5b89\u5168\u6027\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e14\u5c0dIKZF1plus\u7b49\u4e0d\u826f\u9810\u5f8c\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6a23\u9ad8\u6548\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u53ef\u70ba\u65b0\u8a3a\u65b7Ph+ ALL\u60a3\u8005\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f49\u9670\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u70baPh+ ALL\u4e00\u7dda\u6cbb\u7642\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u64da\u3002  SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\/REFRACTORY (R\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY \u4e00\u98051B\u671f\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\uff08R\/R\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u5152\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u8207\u521d\u6b65\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-4691 (PS1473)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\uff08\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u5b78\u7814\u7a76\u6240\uff09  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u5291\u91cf\u905e\u589eIb\u671f\u7814\u7a76\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642\u65e2\u5f80\u22651\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u5152\u7ae5R\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7d4417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f6113\u6b72\uff0c40%\u651c\u5e36ABL1\u7a81\u8b8a\uff08\u542bT315I\uff09\u30029\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u806f\u5408\u6cbb\u7642\u5f8cORR\u9ad8\u905488.9%\uff0cMRD\u9670\u6027\u7387\u905466.7%\uff088\/12\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u5152\uff0814\/15\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\u7372\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7de9\u89e3\uff1b\u5169\u85e5\u5747\u53ef\u900f\u904e\u8840\u8166\u5c4f\u969c\uff0c\u5c0dABL1\u7a81\u8b8a\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u8a72\u7121\u5316\u7642\u53e3\u670d\u96d9\u9776\u5411\u65b9\u6848\u53ef\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u7de9\u89e3\uff0c\u70ba\u5152\u7ae5R\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7642\u9078\u64c7\u3002  REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY \u4e00\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u65bc\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-5454 (PF562)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u570b\u5167\u591a\u4e2d\u5fc3\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff08\u56de\u9867\u6027\uff09\uff0c\u65e8\u5728\u8a55\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u7d0d\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f61\u70ba63\u6b72\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\/CRi\u9ad8\u905472%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7d44\u7642\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u9054\u5230CR\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9670\u6027\u7387\u905461%\u3002NPM1\u7a81\u8b8a\u60a3\u8005CR\/CRi\u7387\u70ba100%\uff0cIDH2 \u7a81\u8b8a\u60a3\u8005\u70ba83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u9054\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7d1a\u6cbb\u7642\u671f\u9593\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u70ba\u8840\u7d30\u80de\u6e1b\u5c11\uff08\u8840\u5c0f\u677f\u6e1b\u5c1127%\uff0c\u8ca7\u884023%\uff0c\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1120%\uff09\uff0c\u6574\u9ad4\u53ef\u63a7\u3002\u8a72\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u6cbb\u7642\u9ad3\u7cfb\u816b\u7624\uff08\u7279\u5225\u662fAML\uff09\u5177\u6709\u512a\u7570\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002  CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY \u4e00\u9805\u95dc\u9375II\u671f\u81e8\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u76f8\u95dc\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3984 (PS1713)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6a39\u6559\u6388\uff0c\u6cb3\u5357\u7701\u816b\u7624\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u57fa\u65bc\u95dc\u9375II\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u95dc\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642R\/R CLL\/SLL\u60a3\u8005\u6642\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\u7814\u7a76\u7d0d\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7642\u3002\u572872\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u70ba23.9\u500b\u6708\uff0cIRC\u8a55\u4f30ORR\u70ba62.5%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0cTP53\u7a81\u8b8a\/del(17p)\u3001\u8907\u96dc\u6838\u578b\u3001\u57fa\u6578\u8f03\u5927\u7684\u816b\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u8b8a\u8207\u8f03\u5dee\u9810\u5f8c\u76f8\u95dc\uff0c\u5176\u4e2d\u8907\u96dc\u6838\u578b\u548c\u816b\u7624\u5927\u5c0f\u662fPFS\u7e2e\u77ed\u7684\u7368\u7acb\u98a8\u96aa\u56e0\u7d20\u3002\u8a72\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7642\u5931\u6557\u5f8c\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u78ba\u7642\u6548\uff0c\u4e26\u53ef\u901a\u904e\u57fa\u7dda\u98a8\u96aa\u7279\u5fb5\u9032\u4e00\u6b65\u8b58\u5225\u9810\u5f8c\u8f03\u5dee\u4eba\u7fa4\uff0c\u70ba\u5f8c\u7e8c\u98a8\u96aa\u5206\u5c64\u548c\u806f\u5408\u6cbb\u7642\u7b56\u7565\u63d0\u4f9b\u4f9d\u64da\u3002  \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u4fc2\u3002\u5982\u9700\u77ad\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u5831\u544a\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=445316\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T01:25:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1990\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b\",\"datePublished\":\"2026-06-15T01:25:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316\"},\"wordCount\":399,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Ascentage_APAC_Logo-3.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316\",\"name\":\"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Ascentage_APAC_Logo-3.jpg\",\"datePublished\":\"2026-06-15T01:25:00+00:00\",\"description\":\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e746\u670815\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u768417\u9805\u81e8\u5e8a\u9032\u5c55\u5df2\u57282026\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9805\u58c1\u5831\u5c55\u793a\u3002\u5c55\u793a\u6578\u64da\u6d89\u53ca\u516c\u53f8\u5169\u5927\u91cd\u78c5\u7522\u54c1\u2014\u2014\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aHQP1351\uff09\u548c\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73fe\u4e86\u516c\u53f8\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6df1\u539a\u4f48\u5c40\u548c\u5168\u7403\u5275\u65b0\u5be6\u529b\u3002 \u5728\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u96d9\u6cbb\u7642\u9818\u57df\u540c\u6b65\u66f4\u65b0\u95dc\u9375\u5faa\u8b49\u6578\u64da\uff1a\u5728CML\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u91dd\u5c0d\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\\\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u5448\u73fe\u5f37\u52c1\u7684\u4e8c\u7dda\u6cbb\u7642\u6f5b\u529b\uff1b\u91dd\u5c0d\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2eTKI\u6cbb\u7642\u4e14\u6cbb\u7642\u5931\u6557\u7684CML-CP\u60a3\u8005\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u70ba\u4e00\u7a2e\u6a19\u6e96\u6cbb\u7642\uff1b\u540c\u6642\u8a72\u7522\u54c1\u91dd\u5c0d\u591a\u7ddaTKI\u8010\u85e5\u3001\u5408\u4f75\u9ad8\u5371\u57fa\u56e0\u7a81\u8b8a\u7684CML\u60a3\u8005\u7684\u81e8\u5e8a\u6578\u64da\u7a4d\u6975\u3002\u5728Ph+ ALL\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6301\u7e8c\u5c55\u73fe\u7a69\u5065\u7642\u6548\uff0c\u5176\u4e00\u7dda\u5168\u7403\u8a3b\u518a\u2162\u671f\uff08POLARIS-1\uff09\u6578\u64da\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u512a\u7570\u7684\u6df1\u5ea6\u7de9\u89e3\u7387\u8207\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u5152\u7ae5\u5fa9\u767c\\\/\u96e3\u6cbb\u6027Ph+ ALL\u7b49\u7d30\u5206\u4eba\u7fa4\u4e2d\uff0c\u8207\u5229\u6c99\u6258\u514b\u62c9\u7684\u7121\u5316\u7642\u806f\u5408\u65b9\u6848\u6536\u7a6b\u4eae\u773c\u81e8\u5e8a\u6578\u64da\u3002 \u5229\u6c99\u6258\u514b\u62c9\u91dd\u5c0d\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u7684\u8a3b\u518a\u2161\u671f\u6578\u64da\u66f4\u65b0\uff0c\u901a\u904e\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u76f8\u95dc\u6027\u5206\u5c64\u5206\u6790\uff0c\u70ba\u5f8c\u7e8c\u7d30\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u85e5\u7b56\u7565\u3001\u512a\u5316\u500b\u9ad4\u5316\u7d66\u85e5\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4e5f\u70ba\u5176\u81e8\u5e8a\u50f9\u503c\u63d0\u4f9b\u4e86\u5f37\u6709\u529b\u7684\u4f50\u8b49\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u5f97\u5c55\u793a\uff0c\u9032\u4e00\u6b65\u8b49\u5be6\u4e86\u9019\u5169\u6b3e\u91cd\u78c5\u7522\u54c1\u5728\u5168\u7403\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6cbb\u7642\u50f9\u503c\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7642\u8def\u5f91\uff0c\u4e5f\u70baPh+ ALL\u60a3\u8005\u6cbb\u7642\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\\\/SLL\u7684\u8a3b\u518aII\u671f\u7684\u6578\u64da\u66f4\u65b0\u70ba\u4e0d\u540c\u4eba\u7fa4\u7684\u500b\u9ad4\u5316\u7528\u85e5\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\uff0c\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4f7f\u6211\u5011\u5c0d\u5176\u5728\u9019\u985e\u60a3\u8005\u7684\u61c9\u7528\u5145\u6eff\u4fe1\u5fc3\u3002\u7279\u5225\u662f\u5169\u500b\u7522\u54c1\u7684\u806f\u7528\u6578\u64da\u5448\u73fe\u7684\u5f37\u52c1\u6f5b\u529b\u8b93\u6211\u5011\u500d\u611f\u8208\u596e\u3002\u672a\u4f86\uff0c\u6211\u5011\u5c07\u7e7c\u7e8c\u52a0\u901f\u63a8\u9032\u5169\u500b\u91cd\u78c5\u7522\u54c1\u7684\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u540c\u6642\u7a4d\u6975\u63a2\u7d22\u66f4\u591a\u5275\u65b0\u806f\u5408\u6cbb\u7642\u65b9\u6848\uff0c\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u8b8a\u9769\u610f\u7fa9\u7684\u6cbb\u7642\u9078\u64c7\u3002\u300d \u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u7cbe\u9078\u58c1\u5831\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u76f8\u95dc\u7814\u7a76\u6578\u64da\u8acb\u67e5\u8a62EHA\u5b98\u7db2\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7dda\u6cbb\u7642\u7684\u6700\u65b0\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aEHA-3388 (PS1733) \u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7684II\u671f\u7814\u7a76\uff0c\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u905476.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u905447.6%\uff0c\u4e14\u53cd\u61c9\u7387\u96a8\u6cbb\u7642\u9031\u671f\u905e\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\\\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u70ba\u9019\u985e\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7dda\u6cbb\u7642\u9078\u64c7\u3002 EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\\\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u57fa\u56e0\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aEHA-3991 (PS1727) \u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805Ib\u671f\u7814\u7a76\uff0c\u5c0d22\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\\\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u7684CP-CML\u60a3\u8005\u9032\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u8b8a\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\\\/22\uff09\u7684\u60a3\u8005\u651c\u5e36ASXL1\u7a81\u8b8a\u3002\u7d93\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5f8c\uff0c44.4%\uff084\\\/9\uff09\u7684ASXL1\u7a81\u8b8a\u60a3\u8005\u7372\u5f97\u81e8\u5e8a\u53cd\u61c9\uff0c\u5176\u4e2d22.2%\uff082\\\/9\uff09\u9054\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u9054\u5230MR4.5\uff09\u3002\u8a72\u7814\u7a76\u9996\u6b21\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\\\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u70ba\u591a\u91cdTKI\u8010\u85e5\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002 THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL \u7d93\u81f3\u5c11\u5169\u7a2e\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f49\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5c0d\u7167\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aEHA-4595 (PS1728) \u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u91ab\u9662 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5c0d\u7167\u8a66\u9a57\uff0c\u7d0d\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u7a2eTKI\u6cbb\u7642\u226518\u500b\u6708\u4f46\u672a\u9054MMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7d44\u3002\u7d50\u679c\u986f\u793a\uff0c6\u500b\u6708\u6642\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44MMR\u7387\u986f\u8457\u9ad8\u65bc\u5c0d\u7167\u7d44\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u500b\u6708\u6642\u7d2f\u7a4dMMR\u7387\u5206\u5225\u70ba57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u898b3-4\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.86%\uff09\u548c\u8ca7\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b78\u4e8b\u4ef6\u7f55\u898b\u300278.57%\u7684\u60a3\u8005\u5728\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u5f8c\uff0c\u65e2\u5f80TKI\u76f8\u95dcAE\u5f97\u5230\u6539\u5584\u3002\u7d50\u8ad6\u652f\u6301\u5967\u96f7\u5df4\u66ff\u5c3c\u4f5c\u70ba\u22652\u7a2eTKI\u6cbb\u7642\u5931\u6557CML-CP\u60a3\u8005\u7684\u6f5b\u5728\u6a19\u6e96\u6cbb\u7642\u3002 UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL POLARIS-1\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aEHA-3437 (PS1479) \u7b2c\u4e00\u4f5c\u8005\uff1a\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9019\u662f\u4e00\u9805\u5168\u7403\u591a\u4e2d\u5fc3\u8a3b\u518a\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u7528\u65bc\u65b0\u8a3a\u65b7Ph+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u5165\u7d4455\u4f8b\u60a3\u8005\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642CR\\\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff09\u9670\u6027CR\u738763.0%\uff1b MRD\u9670\u6027\u7387\u96a8\u6cbb\u7642\u9031\u671f\u63a8\u9032\u6301\u7e8c\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7642\u9031\u671f\u672b\u905493.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u820740mg\u5291\u91cf\u7d44\u7642\u6548\u8207\u5b89\u5168\u6027\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e14\u5c0dIKZF1plus\u7b49\u4e0d\u826f\u9810\u5f8c\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6a23\u9ad8\u6548\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u53ef\u70ba\u65b0\u8a3a\u65b7Ph+ ALL\u60a3\u8005\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f49\u9670\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u70baPh+ ALL\u4e00\u7dda\u6cbb\u7642\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u64da\u3002 SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\\\/REFRACTORY (R\\\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY \u4e00\u98051B\u671f\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\\\/\u96e3\u6cbb\u6027\uff08R\\\/R\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u5152\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u8207\u521d\u6b65\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aEHA-4691 (PS1473) \u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\uff08\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u5b78\u7814\u7a76\u6240\uff09 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u5291\u91cf\u905e\u589eIb\u671f\u7814\u7a76\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642\u65e2\u5f80\u22651\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u5152\u7ae5R\\\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7d4417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f6113\u6b72\uff0c40%\u651c\u5e36ABL1\u7a81\u8b8a\uff08\u542bT315I\uff09\u30029\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u806f\u5408\u6cbb\u7642\u5f8cORR\u9ad8\u905488.9%\uff0cMRD\u9670\u6027\u7387\u905466.7%\uff088\\\/12\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u5152\uff0814\\\/15\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\u7372\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7de9\u89e3\uff1b\u5169\u85e5\u5747\u53ef\u900f\u904e\u8840\u8166\u5c4f\u969c\uff0c\u5c0dABL1\u7a81\u8b8a\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u8a72\u7121\u5316\u7642\u53e3\u670d\u96d9\u9776\u5411\u65b9\u6848\u53ef\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u7de9\u89e3\uff0c\u70ba\u5152\u7ae5R\\\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7642\u9078\u64c7\u3002 REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY \u4e00\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u65bc\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aEHA-5454 (PF562) \u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u570b\u5167\u591a\u4e2d\u5fc3\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff08\u56de\u9867\u6027\uff09\uff0c\u65e8\u5728\u8a55\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u7d0d\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f61\u70ba63\u6b72\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\\\/CRi\u9ad8\u905472%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7d44\u7642\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u9054\u5230CR\\\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9670\u6027\u7387\u905461%\u3002NPM1\u7a81\u8b8a\u60a3\u8005CR\\\/CRi\u7387\u70ba100%\uff0cIDH2 \u7a81\u8b8a\u60a3\u8005\u70ba83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u9054\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7d1a\u6cbb\u7642\u671f\u9593\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u70ba\u8840\u7d30\u80de\u6e1b\u5c11\uff08\u8840\u5c0f\u677f\u6e1b\u5c1127%\uff0c\u8ca7\u884023%\uff0c\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1120%\uff09\uff0c\u6574\u9ad4\u53ef\u63a7\u3002\u8a72\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u6cbb\u7642\u9ad3\u7cfb\u816b\u7624\uff08\u7279\u5225\u662fAML\uff09\u5177\u6709\u512a\u7570\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002 CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\\\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\\\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY \u4e00\u9805\u95dc\u9375II\u671f\u81e8\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u76f8\u95dc\u6027 \u6458\u8981\u7de8\u865f\uff1aEHA-3984 (PS1713) \u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6a39\u6559\u6388\uff0c\u6cb3\u5357\u7701\u816b\u7624\u91ab\u9662 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u57fa\u65bc\u95dc\u9375II\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u95dc\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642R\\\/R CLL\\\/SLL\u60a3\u8005\u6642\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\u7814\u7a76\u7d0d\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7642\u3002\u572872\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u70ba23.9\u500b\u6708\uff0cIRC\u8a55\u4f30ORR\u70ba62.5%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0cTP53\u7a81\u8b8a\\\/del(17p)\u3001\u8907\u96dc\u6838\u578b\u3001\u57fa\u6578\u8f03\u5927\u7684\u816b\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u8b8a\u8207\u8f03\u5dee\u9810\u5f8c\u76f8\u95dc\uff0c\u5176\u4e2d\u8907\u96dc\u6838\u578b\u548c\u816b\u7624\u5927\u5c0f\u662fPFS\u7e2e\u77ed\u7684\u7368\u7acb\u98a8\u96aa\u56e0\u7d20\u3002\u8a72\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7642\u5931\u6557\u5f8c\u7684R\\\/R CLL\\\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u78ba\u7642\u6548\uff0c\u4e26\u53ef\u901a\u904e\u57fa\u7dda\u98a8\u96aa\u7279\u5fb5\u9032\u4e00\u6b65\u8b58\u5225\u9810\u5f8c\u8f03\u5dee\u4eba\u7fa4\uff0c\u70ba\u5f8c\u7e8c\u98a8\u96aa\u5206\u5c64\u548c\u806f\u5408\u6cbb\u7642\u7b56\u7565\u63d0\u4f9b\u4f9d\u64da\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\\\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\\\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\\\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u4fc2\u3002\u5982\u9700\u77ad\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\\\/\\\/ascentage.com\\\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u5831\u544a\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Ascentage_APAC_Logo-3.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Ascentage_APAC_Logo-3.jpg\",\"width\":399,\"height\":150},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=445316#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u768417\u9805\u81e8\u5e8a\u9032\u5c55\u5df2\u57282026\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9805\u58c1\u5831\u5c55\u793a\u3002\u5c55\u793a\u6578\u64da\u6d89\u53ca\u516c\u53f8\u5169\u5927\u91cd\u78c5\u7522\u54c1\u2014\u2014\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aHQP1351\uff09\u548c\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73fe\u4e86\u516c\u53f8\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6df1\u539a\u4f48\u5c40\u548c\u5168\u7403\u5275\u65b0\u5be6\u529b\u3002   \u5728\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u96d9\u6cbb\u7642\u9818\u57df\u540c\u6b65\u66f4\u65b0\u95dc\u9375\u5faa\u8b49\u6578\u64da\uff1a\u5728CML\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u91dd\u5c0d\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u5448\u73fe\u5f37\u52c1\u7684\u4e8c\u7dda\u6cbb\u7642\u6f5b\u529b\uff1b\u91dd\u5c0d\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2eTKI\u6cbb\u7642\u4e14\u6cbb\u7642\u5931\u6557\u7684CML-CP\u60a3\u8005\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u70ba\u4e00\u7a2e\u6a19\u6e96\u6cbb\u7642\uff1b\u540c\u6642\u8a72\u7522\u54c1\u91dd\u5c0d\u591a\u7ddaTKI\u8010\u85e5\u3001\u5408\u4f75\u9ad8\u5371\u57fa\u56e0\u7a81\u8b8a\u7684CML\u60a3\u8005\u7684\u81e8\u5e8a\u6578\u64da\u7a4d\u6975\u3002\u5728Ph+ ALL\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6301\u7e8c\u5c55\u73fe\u7a69\u5065\u7642\u6548\uff0c\u5176\u4e00\u7dda\u5168\u7403\u8a3b\u518a\u2162\u671f\uff08POLARIS-1\uff09\u6578\u64da\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u512a\u7570\u7684\u6df1\u5ea6\u7de9\u89e3\u7387\u8207\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u5152\u7ae5\u5fa9\u767c\/\u96e3\u6cbb\u6027Ph+ ALL\u7b49\u7d30\u5206\u4eba\u7fa4\u4e2d\uff0c\u8207\u5229\u6c99\u6258\u514b\u62c9\u7684\u7121\u5316\u7642\u806f\u5408\u65b9\u6848\u6536\u7a6b\u4eae\u773c\u81e8\u5e8a\u6578\u64da\u3002 \u5229\u6c99\u6258\u514b\u62c9\u91dd\u5c0d\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u8a3b\u518a\u2161\u671f\u6578\u64da\u66f4\u65b0\uff0c\u901a\u904e\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u76f8\u95dc\u6027\u5206\u5c64\u5206\u6790\uff0c\u70ba\u5f8c\u7e8c\u7d30\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u85e5\u7b56\u7565\u3001\u512a\u5316\u500b\u9ad4\u5316\u7d66\u85e5\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4e5f\u70ba\u5176\u81e8\u5e8a\u50f9\u503c\u63d0\u4f9b\u4e86\u5f37\u6709\u529b\u7684\u4f50\u8b49\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u5f97\u5c55\u793a\uff0c\u9032\u4e00\u6b65\u8b49\u5be6\u4e86\u9019\u5169\u6b3e\u91cd\u78c5\u7522\u54c1\u5728\u5168\u7403\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6cbb\u7642\u50f9\u503c\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7642\u8def\u5f91\uff0c\u4e5f\u70baPh+ ALL\u60a3\u8005\u6cbb\u7642\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u8a3b\u518aII\u671f\u7684\u6578\u64da\u66f4\u65b0\u70ba\u4e0d\u540c\u4eba\u7fa4\u7684\u500b\u9ad4\u5316\u7528\u85e5\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\uff0c\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4f7f\u6211\u5011\u5c0d\u5176\u5728\u9019\u985e\u60a3\u8005\u7684\u61c9\u7528\u5145\u6eff\u4fe1\u5fc3\u3002\u7279\u5225\u662f\u5169\u500b\u7522\u54c1\u7684\u806f\u7528\u6578\u64da\u5448\u73fe\u7684\u5f37\u52c1\u6f5b\u529b\u8b93\u6211\u5011\u500d\u611f\u8208\u596e\u3002\u672a\u4f86\uff0c\u6211\u5011\u5c07\u7e7c\u7e8c\u52a0\u901f\u63a8\u9032\u5169\u500b\u91cd\u78c5\u7522\u54c1\u7684\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u540c\u6642\u7a4d\u6975\u63a2\u7d22\u66f4\u591a\u5275\u65b0\u806f\u5408\u6cbb\u7642\u65b9\u6848\uff0c\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u8b8a\u9769\u610f\u7fa9\u7684\u6cbb\u7642\u9078\u64c7\u3002\u300d \u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u7cbe\u9078\u58c1\u5831\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u76f8\u95dc\u7814\u7a76\u6578\u64da\u8acb\u67e5\u8a62EHA\u5b98\u7db2\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7dda\u6cbb\u7642\u7684\u6700\u65b0\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3388 (PS1733)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7684II\u671f\u7814\u7a76\uff0c\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u905476.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u905447.6%\uff0c\u4e14\u53cd\u61c9\u7387\u96a8\u6cbb\u7642\u9031\u671f\u905e\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u70ba\u9019\u985e\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7dda\u6cbb\u7642\u9078\u64c7\u3002  EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u57fa\u56e0\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-3991 (PS1727)  \u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805Ib\u671f\u7814\u7a76\uff0c\u5c0d22\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u7684CP-CML\u60a3\u8005\u9032\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u8b8a\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\/22\uff09\u7684\u60a3\u8005\u651c\u5e36ASXL1\u7a81\u8b8a\u3002\u7d93\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5f8c\uff0c44.4%\uff084\/9\uff09\u7684ASXL1\u7a81\u8b8a\u60a3\u8005\u7372\u5f97\u81e8\u5e8a\u53cd\u61c9\uff0c\u5176\u4e2d22.2%\uff082\/9\uff09\u9054\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u9054\u5230MR4.5\uff09\u3002\u8a72\u7814\u7a76\u9996\u6b21\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u70ba\u591a\u91cdTKI\u8010\u85e5\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002  THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL \u7d93\u81f3\u5c11\u5169\u7a2e\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f49\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5c0d\u7167\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-4595 (PS1728)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5c0d\u7167\u8a66\u9a57\uff0c\u7d0d\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u7a2eTKI\u6cbb\u7642\u226518\u500b\u6708\u4f46\u672a\u9054MMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7d44\u3002\u7d50\u679c\u986f\u793a\uff0c6\u500b\u6708\u6642\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44MMR\u7387\u986f\u8457\u9ad8\u65bc\u5c0d\u7167\u7d44\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u500b\u6708\u6642\u7d2f\u7a4dMMR\u7387\u5206\u5225\u70ba57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u898b3-4\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.86%\uff09\u548c\u8ca7\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b78\u4e8b\u4ef6\u7f55\u898b\u300278.57%\u7684\u60a3\u8005\u5728\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u5f8c\uff0c\u65e2\u5f80TKI\u76f8\u95dcAE\u5f97\u5230\u6539\u5584\u3002\u7d50\u8ad6\u652f\u6301\u5967\u96f7\u5df4\u66ff\u5c3c\u4f5c\u70ba\u22652\u7a2eTKI\u6cbb\u7642\u5931\u6557CML-CP\u60a3\u8005\u7684\u6f5b\u5728\u6a19\u6e96\u6cbb\u7642\u3002  UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL POLARIS-1\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-3437 (PS1479)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662  \u9019\u662f\u4e00\u9805\u5168\u7403\u591a\u4e2d\u5fc3\u8a3b\u518a\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u7528\u65bc\u65b0\u8a3a\u65b7Ph+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u5165\u7d4455\u4f8b\u60a3\u8005\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642CR\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff09\u9670\u6027CR\u738763.0%\uff1b MRD\u9670\u6027\u7387\u96a8\u6cbb\u7642\u9031\u671f\u63a8\u9032\u6301\u7e8c\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7642\u9031\u671f\u672b\u905493.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u820740mg\u5291\u91cf\u7d44\u7642\u6548\u8207\u5b89\u5168\u6027\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e14\u5c0dIKZF1plus\u7b49\u4e0d\u826f\u9810\u5f8c\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6a23\u9ad8\u6548\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u53ef\u70ba\u65b0\u8a3a\u65b7Ph+ ALL\u60a3\u8005\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f49\u9670\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u70baPh+ ALL\u4e00\u7dda\u6cbb\u7642\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u64da\u3002  SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\/REFRACTORY (R\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY \u4e00\u98051B\u671f\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\uff08R\/R\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u5152\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u8207\u521d\u6b65\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-4691 (PS1473)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\uff08\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u5b78\u7814\u7a76\u6240\uff09  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u5291\u91cf\u905e\u589eIb\u671f\u7814\u7a76\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642\u65e2\u5f80\u22651\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u5152\u7ae5R\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7d4417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f6113\u6b72\uff0c40%\u651c\u5e36ABL1\u7a81\u8b8a\uff08\u542bT315I\uff09\u30029\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u806f\u5408\u6cbb\u7642\u5f8cORR\u9ad8\u905488.9%\uff0cMRD\u9670\u6027\u7387\u905466.7%\uff088\/12\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u5152\uff0814\/15\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\u7372\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7de9\u89e3\uff1b\u5169\u85e5\u5747\u53ef\u900f\u904e\u8840\u8166\u5c4f\u969c\uff0c\u5c0dABL1\u7a81\u8b8a\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u8a72\u7121\u5316\u7642\u53e3\u670d\u96d9\u9776\u5411\u65b9\u6848\u53ef\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u7de9\u89e3\uff0c\u70ba\u5152\u7ae5R\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7642\u9078\u64c7\u3002  REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY \u4e00\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u65bc\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-5454 (PF562)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u570b\u5167\u591a\u4e2d\u5fc3\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff08\u56de\u9867\u6027\uff09\uff0c\u65e8\u5728\u8a55\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u7d0d\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f61\u70ba63\u6b72\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\/CRi\u9ad8\u905472%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7d44\u7642\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u9054\u5230CR\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9670\u6027\u7387\u905461%\u3002NPM1\u7a81\u8b8a\u60a3\u8005CR\/CRi\u7387\u70ba100%\uff0cIDH2 \u7a81\u8b8a\u60a3\u8005\u70ba83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u9054\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7d1a\u6cbb\u7642\u671f\u9593\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u70ba\u8840\u7d30\u80de\u6e1b\u5c11\uff08\u8840\u5c0f\u677f\u6e1b\u5c1127%\uff0c\u8ca7\u884023%\uff0c\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1120%\uff09\uff0c\u6574\u9ad4\u53ef\u63a7\u3002\u8a72\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u6cbb\u7642\u9ad3\u7cfb\u816b\u7624\uff08\u7279\u5225\u662fAML\uff09\u5177\u6709\u512a\u7570\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002  CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY \u4e00\u9805\u95dc\u9375II\u671f\u81e8\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u76f8\u95dc\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3984 (PS1713)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6a39\u6559\u6388\uff0c\u6cb3\u5357\u7701\u816b\u7624\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u57fa\u65bc\u95dc\u9375II\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u95dc\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642R\/R CLL\/SLL\u60a3\u8005\u6642\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\u7814\u7a76\u7d0d\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7642\u3002\u572872\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u70ba23.9\u500b\u6708\uff0cIRC\u8a55\u4f30ORR\u70ba62.5%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0cTP53\u7a81\u8b8a\/del(17p)\u3001\u8907\u96dc\u6838\u578b\u3001\u57fa\u6578\u8f03\u5927\u7684\u816b\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u8b8a\u8207\u8f03\u5dee\u9810\u5f8c\u76f8\u95dc\uff0c\u5176\u4e2d\u8907\u96dc\u6838\u578b\u548c\u816b\u7624\u5927\u5c0f\u662fPFS\u7e2e\u77ed\u7684\u7368\u7acb\u98a8\u96aa\u56e0\u7d20\u3002\u8a72\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7642\u5931\u6557\u5f8c\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u78ba\u7642\u6548\uff0c\u4e26\u53ef\u901a\u904e\u57fa\u7dda\u98a8\u96aa\u7279\u5fb5\u9032\u4e00\u6b65\u8b58\u5225\u9810\u5f8c\u8f03\u5dee\u4eba\u7fa4\uff0c\u70ba\u5f8c\u7e8c\u98a8\u96aa\u5206\u5c64\u548c\u806f\u5408\u6cbb\u7642\u7b56\u7565\u63d0\u4f9b\u4f9d\u64da\u3002  \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u4fc2\u3002\u5982\u9700\u77ad\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u5831\u544a\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=445316","og_locale":"zh_TW","og_type":"article","og_title":"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u768417\u9805\u81e8\u5e8a\u9032\u5c55\u5df2\u57282026\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9805\u58c1\u5831\u5c55\u793a\u3002\u5c55\u793a\u6578\u64da\u6d89\u53ca\u516c\u53f8\u5169\u5927\u91cd\u78c5\u7522\u54c1\u2014\u2014\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aHQP1351\uff09\u548c\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73fe\u4e86\u516c\u53f8\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6df1\u539a\u4f48\u5c40\u548c\u5168\u7403\u5275\u65b0\u5be6\u529b\u3002   \u5728\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u96d9\u6cbb\u7642\u9818\u57df\u540c\u6b65\u66f4\u65b0\u95dc\u9375\u5faa\u8b49\u6578\u64da\uff1a\u5728CML\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u91dd\u5c0d\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u5448\u73fe\u5f37\u52c1\u7684\u4e8c\u7dda\u6cbb\u7642\u6f5b\u529b\uff1b\u91dd\u5c0d\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2eTKI\u6cbb\u7642\u4e14\u6cbb\u7642\u5931\u6557\u7684CML-CP\u60a3\u8005\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u70ba\u4e00\u7a2e\u6a19\u6e96\u6cbb\u7642\uff1b\u540c\u6642\u8a72\u7522\u54c1\u91dd\u5c0d\u591a\u7ddaTKI\u8010\u85e5\u3001\u5408\u4f75\u9ad8\u5371\u57fa\u56e0\u7a81\u8b8a\u7684CML\u60a3\u8005\u7684\u81e8\u5e8a\u6578\u64da\u7a4d\u6975\u3002\u5728Ph+ ALL\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6301\u7e8c\u5c55\u73fe\u7a69\u5065\u7642\u6548\uff0c\u5176\u4e00\u7dda\u5168\u7403\u8a3b\u518a\u2162\u671f\uff08POLARIS-1\uff09\u6578\u64da\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u512a\u7570\u7684\u6df1\u5ea6\u7de9\u89e3\u7387\u8207\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u5152\u7ae5\u5fa9\u767c\/\u96e3\u6cbb\u6027Ph+ ALL\u7b49\u7d30\u5206\u4eba\u7fa4\u4e2d\uff0c\u8207\u5229\u6c99\u6258\u514b\u62c9\u7684\u7121\u5316\u7642\u806f\u5408\u65b9\u6848\u6536\u7a6b\u4eae\u773c\u81e8\u5e8a\u6578\u64da\u3002 \u5229\u6c99\u6258\u514b\u62c9\u91dd\u5c0d\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u8a3b\u518a\u2161\u671f\u6578\u64da\u66f4\u65b0\uff0c\u901a\u904e\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u76f8\u95dc\u6027\u5206\u5c64\u5206\u6790\uff0c\u70ba\u5f8c\u7e8c\u7d30\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u85e5\u7b56\u7565\u3001\u512a\u5316\u500b\u9ad4\u5316\u7d66\u85e5\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4e5f\u70ba\u5176\u81e8\u5e8a\u50f9\u503c\u63d0\u4f9b\u4e86\u5f37\u6709\u529b\u7684\u4f50\u8b49\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u5f97\u5c55\u793a\uff0c\u9032\u4e00\u6b65\u8b49\u5be6\u4e86\u9019\u5169\u6b3e\u91cd\u78c5\u7522\u54c1\u5728\u5168\u7403\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6cbb\u7642\u50f9\u503c\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7642\u8def\u5f91\uff0c\u4e5f\u70baPh+ ALL\u60a3\u8005\u6cbb\u7642\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u8a3b\u518aII\u671f\u7684\u6578\u64da\u66f4\u65b0\u70ba\u4e0d\u540c\u4eba\u7fa4\u7684\u500b\u9ad4\u5316\u7528\u85e5\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\uff0c\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4f7f\u6211\u5011\u5c0d\u5176\u5728\u9019\u985e\u60a3\u8005\u7684\u61c9\u7528\u5145\u6eff\u4fe1\u5fc3\u3002\u7279\u5225\u662f\u5169\u500b\u7522\u54c1\u7684\u806f\u7528\u6578\u64da\u5448\u73fe\u7684\u5f37\u52c1\u6f5b\u529b\u8b93\u6211\u5011\u500d\u611f\u8208\u596e\u3002\u672a\u4f86\uff0c\u6211\u5011\u5c07\u7e7c\u7e8c\u52a0\u901f\u63a8\u9032\u5169\u500b\u91cd\u78c5\u7522\u54c1\u7684\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u540c\u6642\u7a4d\u6975\u63a2\u7d22\u66f4\u591a\u5275\u65b0\u806f\u5408\u6cbb\u7642\u65b9\u6848\uff0c\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u8b8a\u9769\u610f\u7fa9\u7684\u6cbb\u7642\u9078\u64c7\u3002\u300d \u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u7cbe\u9078\u58c1\u5831\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u76f8\u95dc\u7814\u7a76\u6578\u64da\u8acb\u67e5\u8a62EHA\u5b98\u7db2\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7dda\u6cbb\u7642\u7684\u6700\u65b0\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3388 (PS1733)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7684II\u671f\u7814\u7a76\uff0c\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u905476.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u905447.6%\uff0c\u4e14\u53cd\u61c9\u7387\u96a8\u6cbb\u7642\u9031\u671f\u905e\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u70ba\u9019\u985e\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7dda\u6cbb\u7642\u9078\u64c7\u3002  EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u57fa\u56e0\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-3991 (PS1727)  \u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805Ib\u671f\u7814\u7a76\uff0c\u5c0d22\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u7684CP-CML\u60a3\u8005\u9032\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u8b8a\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\/22\uff09\u7684\u60a3\u8005\u651c\u5e36ASXL1\u7a81\u8b8a\u3002\u7d93\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5f8c\uff0c44.4%\uff084\/9\uff09\u7684ASXL1\u7a81\u8b8a\u60a3\u8005\u7372\u5f97\u81e8\u5e8a\u53cd\u61c9\uff0c\u5176\u4e2d22.2%\uff082\/9\uff09\u9054\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u9054\u5230MR4.5\uff09\u3002\u8a72\u7814\u7a76\u9996\u6b21\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u70ba\u591a\u91cdTKI\u8010\u85e5\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002  THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL \u7d93\u81f3\u5c11\u5169\u7a2e\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f49\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5c0d\u7167\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-4595 (PS1728)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5c0d\u7167\u8a66\u9a57\uff0c\u7d0d\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u7a2eTKI\u6cbb\u7642\u226518\u500b\u6708\u4f46\u672a\u9054MMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7d44\u3002\u7d50\u679c\u986f\u793a\uff0c6\u500b\u6708\u6642\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44MMR\u7387\u986f\u8457\u9ad8\u65bc\u5c0d\u7167\u7d44\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u500b\u6708\u6642\u7d2f\u7a4dMMR\u7387\u5206\u5225\u70ba57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u898b3-4\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.86%\uff09\u548c\u8ca7\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b78\u4e8b\u4ef6\u7f55\u898b\u300278.57%\u7684\u60a3\u8005\u5728\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u5f8c\uff0c\u65e2\u5f80TKI\u76f8\u95dcAE\u5f97\u5230\u6539\u5584\u3002\u7d50\u8ad6\u652f\u6301\u5967\u96f7\u5df4\u66ff\u5c3c\u4f5c\u70ba\u22652\u7a2eTKI\u6cbb\u7642\u5931\u6557CML-CP\u60a3\u8005\u7684\u6f5b\u5728\u6a19\u6e96\u6cbb\u7642\u3002  UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL POLARIS-1\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76   \u6458\u8981\u7de8\u865f\uff1aEHA-3437 (PS1479)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662  \u9019\u662f\u4e00\u9805\u5168\u7403\u591a\u4e2d\u5fc3\u8a3b\u518a\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u7528\u65bc\u65b0\u8a3a\u65b7Ph+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u5165\u7d4455\u4f8b\u60a3\u8005\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642CR\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff09\u9670\u6027CR\u738763.0%\uff1b MRD\u9670\u6027\u7387\u96a8\u6cbb\u7642\u9031\u671f\u63a8\u9032\u6301\u7e8c\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7642\u9031\u671f\u672b\u905493.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u820740mg\u5291\u91cf\u7d44\u7642\u6548\u8207\u5b89\u5168\u6027\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e14\u5c0dIKZF1plus\u7b49\u4e0d\u826f\u9810\u5f8c\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6a23\u9ad8\u6548\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u53ef\u70ba\u65b0\u8a3a\u65b7Ph+ ALL\u60a3\u8005\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f49\u9670\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u70baPh+ ALL\u4e00\u7dda\u6cbb\u7642\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u64da\u3002  SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\/REFRACTORY (R\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY \u4e00\u98051B\u671f\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\uff08R\/R\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u5152\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u8207\u521d\u6b65\u7642\u6548   \u6458\u8981\u7de8\u865f\uff1aEHA-4691 (PS1473)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\uff08\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u5b78\u7814\u7a76\u6240\uff09  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u5291\u91cf\u905e\u589eIb\u671f\u7814\u7a76\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642\u65e2\u5f80\u22651\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u5152\u7ae5R\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7d4417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f6113\u6b72\uff0c40%\u651c\u5e36ABL1\u7a81\u8b8a\uff08\u542bT315I\uff09\u30029\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u806f\u5408\u6cbb\u7642\u5f8cORR\u9ad8\u905488.9%\uff0cMRD\u9670\u6027\u7387\u905466.7%\uff088\/12\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u5152\uff0814\/15\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\u7372\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7de9\u89e3\uff1b\u5169\u85e5\u5747\u53ef\u900f\u904e\u8840\u8166\u5c4f\u969c\uff0c\u5c0dABL1\u7a81\u8b8a\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u8a72\u7121\u5316\u7642\u53e3\u670d\u96d9\u9776\u5411\u65b9\u6848\u53ef\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u7de9\u89e3\uff0c\u70ba\u5152\u7ae5R\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7642\u9078\u64c7\u3002  REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY \u4e00\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u65bc\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-5454 (PF562)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u570b\u5167\u591a\u4e2d\u5fc3\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff08\u56de\u9867\u6027\uff09\uff0c\u65e8\u5728\u8a55\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u7d0d\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f61\u70ba63\u6b72\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\/CRi\u9ad8\u905472%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7d44\u7642\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u9054\u5230CR\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9670\u6027\u7387\u905461%\u3002NPM1\u7a81\u8b8a\u60a3\u8005CR\/CRi\u7387\u70ba100%\uff0cIDH2 \u7a81\u8b8a\u60a3\u8005\u70ba83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u9054\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7d1a\u6cbb\u7642\u671f\u9593\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u70ba\u8840\u7d30\u80de\u6e1b\u5c11\uff08\u8840\u5c0f\u677f\u6e1b\u5c1127%\uff0c\u8ca7\u884023%\uff0c\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1120%\uff09\uff0c\u6574\u9ad4\u53ef\u63a7\u3002\u8a72\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u6cbb\u7642\u9ad3\u7cfb\u816b\u7624\uff08\u7279\u5225\u662fAML\uff09\u5177\u6709\u512a\u7570\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002  CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY \u4e00\u9805\u95dc\u9375II\u671f\u81e8\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u76f8\u95dc\u6027   \u6458\u8981\u7de8\u865f\uff1aEHA-3984 (PS1713)  \u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6a39\u6559\u6388\uff0c\u6cb3\u5357\u7701\u816b\u7624\u91ab\u9662  \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u57fa\u65bc\u95dc\u9375II\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u95dc\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642R\/R CLL\/SLL\u60a3\u8005\u6642\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\u7814\u7a76\u7d0d\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7642\u3002\u572872\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u70ba23.9\u500b\u6708\uff0cIRC\u8a55\u4f30ORR\u70ba62.5%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0cTP53\u7a81\u8b8a\/del(17p)\u3001\u8907\u96dc\u6838\u578b\u3001\u57fa\u6578\u8f03\u5927\u7684\u816b\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u8b8a\u8207\u8f03\u5dee\u9810\u5f8c\u76f8\u95dc\uff0c\u5176\u4e2d\u8907\u96dc\u6838\u578b\u548c\u816b\u7624\u5927\u5c0f\u662fPFS\u7e2e\u77ed\u7684\u7368\u7acb\u98a8\u96aa\u56e0\u7d20\u3002\u8a72\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7642\u5931\u6557\u5f8c\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u78ba\u7642\u6548\uff0c\u4e26\u53ef\u901a\u904e\u57fa\u7dda\u98a8\u96aa\u7279\u5fb5\u9032\u4e00\u6b65\u8b58\u5225\u9810\u5f8c\u8f03\u5dee\u4eba\u7fa4\uff0c\u70ba\u5f8c\u7e8c\u98a8\u96aa\u5206\u5c64\u548c\u806f\u5408\u6cbb\u7642\u7b56\u7565\u63d0\u4f9b\u4f9d\u64da\u3002  \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u4fc2\u3002\u5982\u9700\u77ad\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u5831\u544a\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","og_url":"https:\/\/pingtungtimes.com.tw\/?p=445316","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2026-06-15T01:25:00+00:00","og_image":[{"width":3000,"height":1990,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=445316#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445316"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b","datePublished":"2026-06-15T01:25:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445316"},"wordCount":399,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445316#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-3.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=445316","url":"https:\/\/pingtungtimes.com.tw\/?p=445316","name":"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445316#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445316#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-3.jpg","datePublished":"2026-06-15T01:25:00+00:00","description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2026\u5e746\u670815\u65e5 \/\u7f8e\u901a\u793e\/ -- \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u4f48\uff0c\u516c\u53f8\u6838\u5fc3\u7522\u54c1\u768417\u9805\u81e8\u5e8a\u9032\u5c55\u5df2\u57282026\u5e74\u6b50\u6d32\u8840\u6db2\u5b78\u5354\u6703\uff08EHA\uff09\u5e74\u6703\u4e0a\u7cbe\u5f69\u4eae\u76f8\uff0c\u5176\u4e2d\u5305\u62ec8\u9805\u58c1\u5831\u5c55\u793a\u3002\u5c55\u793a\u6578\u64da\u6d89\u53ca\u516c\u53f8\u5169\u5927\u91cd\u78c5\u7522\u54c1\u2014\u2014\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aHQP1351\uff09\u548c\u4e2d\u570b\u9996\u500b\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u9078\u64c7\u6027\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\uff08\u5546\u54c1\u540d\uff1a\u5229\u751f\u59a5\u00ae\uff1b\u7814\u767c\u4ee3\u865f\uff1aAPG-2575\uff09\uff0c\u5168\u9762\u5c55\u73fe\u4e86\u516c\u53f8\u5728\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6df1\u539a\u4f48\u5c40\u548c\u5168\u7403\u5275\u65b0\u5be6\u529b\u3002 \u5728\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML\uff09\u548c\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u96d9\u6cbb\u7642\u9818\u57df\u540c\u6b65\u66f4\u65b0\u95dc\u9375\u5faa\u8b49\u6578\u64da\uff1a\u5728CML\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u91dd\u5c0d\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CML\u6162\u6027\u671f\uff08CML-CP\uff09\u60a3\u8005\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u5448\u73fe\u5f37\u52c1\u7684\u4e8c\u7dda\u6cbb\u7642\u6f5b\u529b\uff1b\u91dd\u5c0d\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2eTKI\u6cbb\u7642\u4e14\u6cbb\u7642\u5931\u6557\u7684CML-CP\u60a3\u8005\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u4ee5\u4f5c\u70ba\u4e00\u7a2e\u6a19\u6e96\u6cbb\u7642\uff1b\u540c\u6642\u8a72\u7522\u54c1\u91dd\u5c0d\u591a\u7ddaTKI\u8010\u85e5\u3001\u5408\u4f75\u9ad8\u5371\u57fa\u56e0\u7a81\u8b8a\u7684CML\u60a3\u8005\u7684\u81e8\u5e8a\u6578\u64da\u7a4d\u6975\u3002\u5728Ph+ ALL\u9818\u57df\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6301\u7e8c\u5c55\u73fe\u7a69\u5065\u7642\u6548\uff0c\u5176\u4e00\u7dda\u5168\u7403\u8a3b\u518a\u2162\u671f\uff08POLARIS-1\uff09\u6578\u64da\u9032\u4e00\u6b65\u9a57\u8b49\u4e86\u5176\u512a\u7570\u7684\u6df1\u5ea6\u7de9\u89e3\u7387\u8207\u5b89\u5168\u53ef\u63a7\u6027\uff1b\u800c\u5728\u5152\u7ae5\u5fa9\u767c\/\u96e3\u6cbb\u6027Ph+ ALL\u7b49\u7d30\u5206\u4eba\u7fa4\u4e2d\uff0c\u8207\u5229\u6c99\u6258\u514b\u62c9\u7684\u7121\u5316\u7642\u806f\u5408\u65b9\u6848\u6536\u7a6b\u4eae\u773c\u81e8\u5e8a\u6578\u64da\u3002 \u5229\u6c99\u6258\u514b\u62c9\u91dd\u5c0d\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u7684\u8a3b\u518a\u2161\u671f\u6578\u64da\u66f4\u65b0\uff0c\u901a\u904e\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u76f8\u95dc\u6027\u5206\u5c64\u5206\u6790\uff0c\u70ba\u5f8c\u7e8c\u7d30\u5316\u4e0d\u540c\u4eba\u7fa4\u7528\u85e5\u7b56\u7565\u3001\u512a\u5316\u500b\u9ad4\u5316\u7d66\u85e5\u65b9\u6848\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4e5f\u70ba\u5176\u81e8\u5e8a\u50f9\u503c\u63d0\u4f9b\u4e86\u5f37\u6709\u529b\u7684\u4f50\u8b49\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u672c\u5c46EHA\u5e74\u6703\u4e0a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u3001\u5229\u6c99\u6258\u514b\u62c9\u7684\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u5f97\u5c55\u793a\uff0c\u9032\u4e00\u6b65\u8b49\u5be6\u4e86\u9019\u5169\u6b3e\u91cd\u78c5\u7522\u54c1\u5728\u5168\u7403\u8840\u6db2\u816b\u7624\u9818\u57df\u7684\u6cbb\u7642\u50f9\u503c\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u6709\u671b\u91cd\u5851CML\u7684\u6cbb\u7642\u8def\u5f91\uff0c\u4e5f\u70baPh+ ALL\u60a3\u8005\u6cbb\u7642\u63d0\u4f9b\u5168\u65b0\u53ef\u80fd\u3002\u5229\u6c99\u6258\u514b\u62c9\u5728CLL\/SLL\u7684\u8a3b\u518aII\u671f\u7684\u6578\u64da\u66f4\u65b0\u70ba\u4e0d\u540c\u4eba\u7fa4\u7684\u500b\u9ad4\u5316\u7528\u85e5\u63d0\u4f9b\u4e86\u91cd\u8981\u53c3\u8003\uff0c\u5728\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u4f7f\u6211\u5011\u5c0d\u5176\u5728\u9019\u985e\u60a3\u8005\u7684\u61c9\u7528\u5145\u6eff\u4fe1\u5fc3\u3002\u7279\u5225\u662f\u5169\u500b\u7522\u54c1\u7684\u806f\u7528\u6578\u64da\u5448\u73fe\u7684\u5f37\u52c1\u6f5b\u529b\u8b93\u6211\u5011\u500d\u611f\u8208\u596e\u3002\u672a\u4f86\uff0c\u6211\u5011\u5c07\u7e7c\u7e8c\u52a0\u901f\u63a8\u9032\u5169\u500b\u91cd\u78c5\u7522\u54c1\u7684\u5168\u7403\u81e8\u5e8a\u958b\u767c\u9032\u7a0b\uff0c\u540c\u6642\u7a4d\u6975\u63a2\u7d22\u66f4\u591a\u5275\u65b0\u806f\u5408\u6cbb\u7642\u65b9\u6848\uff0c\u70ba\u5168\u7403\u60a3\u8005\u63d0\u4f9b\u771f\u6b63\u5177\u6709\u8b8a\u9769\u610f\u7fa9\u7684\u6cbb\u7642\u9078\u64c7\u3002\u300d \u5728\u6b64\u6b21EHA\u5e74\u6703\u4e0a\u5c55\u793a\u7684\u7cbe\u9078\u58c1\u5831\u6838\u5fc3\u8981\u9ede\u5982\u4e0b\uff08\u66f4\u591a\u516c\u53f8\u5728\u7814\u54c1\u7a2e\u76f8\u95dc\u7814\u7a76\u6578\u64da\u8acb\u67e5\u8a62EHA\u5b98\u7db2\uff09\uff1a UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) \u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u4f5c\u70ba\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u4e8c\u7dda\u6cbb\u7642\u7684\u6700\u65b0\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aEHA-3388 (PS1733) \u7b2c\u4e00\u4f5c\u8005\uff1a\u9ece\u7def\u660e\u6559\u6388\uff0c\u83ef\u4e2d\u79d1\u6280\u5927\u5b78\u540c\u6fdf\u91ab\u5b78\u9662\u9644\u5c6c\u5354\u548c\u91ab\u9662\u8840\u6db2\u79d1 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u3001\u958b\u653e\u6a19\u7c64\u7684II\u671f\u7814\u7a76\uff0c\u8a55\u4f30\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642\u6548\u679c\u3002\u572842\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u905476.2%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u905447.6%\uff0c\u4e14\u53cd\u61c9\u7387\u96a8\u6cbb\u7642\u9031\u671f\u905e\u589e\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u7121T315I\u7a81\u8b8a\u7684\u4e00\u7ddaTKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7CP-CML\u60a3\u8005\u4e2d\u5177\u6709\u6301\u4e45\u4e14\u6df1\u5ea6\u7684\u6cbb\u7642\u6548\u679c\uff0c\u70ba\u9019\u985e\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u4e8c\u7dda\u6cbb\u7642\u9078\u64c7\u3002 EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u65e2\u5f80\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u57fa\u56e0\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CP-CML\uff09\u60a3\u8005\u7684\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aEHA-3991 (PS1727) \u7b2c\u4e00\u4f5c\u8005\uff1aElias Jabbour, MD\uff0c\u7f8e\u570b\u5fb7\u514b\u85a9\u65af\u5927\u5b78MD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u767d\u8840\u75c5\u79d1 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805Ib\u671f\u7814\u7a76\uff0c\u5c0d22\u4f8b\u65e2\u5f80\u63a5\u53d7\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u7684CP-CML\u60a3\u8005\u9032\u884c\u57fa\u56e0\u5206\u6790\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e0d\u540c\u7a81\u8b8a\u80cc\u666f\u4e0b\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u300240.9%\uff089\/22\uff09\u7684\u60a3\u8005\u651c\u5e36ASXL1\u7a81\u8b8a\u3002\u7d93\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u5f8c\uff0c44.4%\uff084\/9\uff09\u7684ASXL1\u7a81\u8b8a\u60a3\u8005\u7372\u5f97\u81e8\u5e8a\u53cd\u61c9\uff0c\u5176\u4e2d22.2%\uff082\/9\uff09\u9054\u5230MMR\uff08\u5176\u4e2d1\u4f8b\u9054\u5230MR4.5\uff09\u3002\u8a72\u7814\u7a76\u9996\u6b21\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u5c0d\u6cca\u90a3\u66ff\u5c3c\u548c\/\u6216\u963f\u601d\u5c3c\u5e03\u8010\u85e5\u4e14\u651c\u5e36ASXL1\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u6709\u6548\uff0c\u70ba\u591a\u91cdTKI\u8010\u85e5\u60a3\u8005\u63d0\u4f9b\u4e86\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002 THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL \u7d93\u81f3\u5c11\u5169\u7a2e\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\u8f49\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a\u4e00\u9805\u524d\u77bb\u6027\u591a\u4e2d\u5fc3\u5c0d\u7167\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aEHA-4595 (PS1728) \u7b2c\u4e00\u4f5c\u8005\uff1a\u6587\u51b0\u51b0\uff0c\u6df1\u5733\u5e02\u7b2c\u4e8c\u4eba\u6c11\u91ab\u9662 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u5c0d\u7167\u8a66\u9a57\uff0c\u7d0d\u5165105\u4f8b\u65e2\u5f80\u63a5\u53d7\u22652\u7a2eTKI\u6cbb\u7642\u226518\u500b\u6708\u4f46\u672a\u9054MMR\u7684CML-CP\u60a3\u8005\uff0c\u63091:2\u5206\u914d\u81f3\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44\uff0840mg\u9694\u65e5\u53e3\u670d\uff09\u6216\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7d44\u3002\u7d50\u679c\u986f\u793a\uff0c6\u500b\u6708\u6642\u5967\u96f7\u5df4\u66ff\u5c3c\u7d44MMR\u7387\u986f\u8457\u9ad8\u65bc\u5c0d\u7167\u7d44\uff0854.3% vs 10.0%\uff0cP&lt;0.001\uff09\uff1b12\u500b\u6708\u6642\u7d2f\u7a4dMMR\u7387\u5206\u5225\u70ba57.14%\u548c21.43%\uff08P&lt;0.0001\uff09\u3002\u6700\u5e38\u898b3-4\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.86%\uff09\u548c\u8ca7\u8840\uff0817.14%\uff09\uff0c\u975e\u8840\u6db2\u5b78\u4e8b\u4ef6\u7f55\u898b\u300278.57%\u7684\u60a3\u8005\u5728\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u5f8c\uff0c\u65e2\u5f80TKI\u76f8\u95dcAE\u5f97\u5230\u6539\u5584\u3002\u7d50\u8ad6\u652f\u6301\u5967\u96f7\u5df4\u66ff\u5c3c\u4f5c\u70ba\u22652\u7a2eTKI\u6cbb\u7642\u5931\u6557CML-CP\u60a3\u8005\u7684\u6f5b\u5728\u6a19\u6e96\u6cbb\u7642\u3002 UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL POLARIS-1\u7814\u7a76\uff08\u7b2c\u4e00\u90e8\u5206\uff09\u6700\u65b0\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u7684\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76 \u6458\u8981\u7de8\u865f\uff1aEHA-3437 (PS1479) \u7b2c\u4e00\u4f5c\u8005\uff1a\u9673\u8607\u5be7\u6559\u6388\uff0c\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9019\u662f\u4e00\u9805\u5168\u7403\u591a\u4e2d\u5fc3\u8a3b\u518a\u6027III\u671f\u7814\u7a76\uff08POLARIS-1\u7b2c\u4e00\u90e8\u5206\uff09\uff0c\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u7528\u65bc\u65b0\u8a3a\u65b7Ph+ ALL\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u5165\u7d4455\u4f8b\u60a3\u8005\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642CR\/CRi\u738794.4%\uff0c\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff09\u9670\u6027CR\u738763.0%\uff1b MRD\u9670\u6027\u7387\u96a8\u6cbb\u7642\u9031\u671f\u63a8\u9032\u6301\u7e8c\u5347\u9ad8\uff0c\u81f3\u7b2c9\u6cbb\u7642\u9031\u671f\u672b\u905493.1%\uff1b\u5b89\u5168\u6027\u53ef\u63a7\uff0c30mg\u820740mg\u5291\u91cf\u7d44\u7642\u6548\u8207\u5b89\u5168\u6027\u7121\u986f\u8457\u5dee\u7570\uff0c\u4e14\u5c0dIKZF1plus\u7b49\u4e0d\u826f\u9810\u5f8c\u57fa\u56e0\u578b\u60a3\u8005\u540c\u6a23\u9ad8\u6548\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u53ef\u70ba\u65b0\u8a3a\u65b7Ph+ ALL\u60a3\u8005\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u4e14\u6301\u4e45\u7684MRD\u8f49\u9670\uff0c\u5b89\u5168\u6027\u826f\u597d\uff0c\u70baPh+ ALL\u4e00\u7dda\u6cbb\u7642\u63d0\u4f9b\u4e86\u91cd\u8981\u4f9d\u64da\u3002 SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED\/REFRACTORY (R\/R PH+ ALL): RESULTS OF A PHASE 1B STUDY \u4e00\u98051B\u671f\u81e8\u5e8a\u7814\u7a76\u7d50\u679c\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\uff08R\/R\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u5152\u7ae5\u60a3\u8005\u7684\u5b89\u5168\u6027\u8207\u521d\u6b65\u7642\u6548 \u6458\u8981\u7de8\u865f\uff1aEHA-4691 (PS1473) \u7b2c\u4e00\u4f5c\u8005\uff1a\u7ae0\u5a67\u5afd\uff0c\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\uff08\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u5b78\u7814\u7a76\u6240\uff09 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u3001\u5291\u91cf\u905e\u589eIb\u671f\u7814\u7a76\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642\u65e2\u5f80\u22651\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u5152\u7ae5R\/R Ph+ ALL\u60a3\u8005\u3002\u5171\u5165\u7d4417\u4f8b\u60a3\u8005\uff0c\u4e2d\u4f4d\u5e74\u9f6113\u6b72\uff0c40%\u651c\u5e36ABL1\u7a81\u8b8a\uff08\u542bT315I\uff09\u30029\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c\u806f\u5408\u6cbb\u7642\u5f8cORR\u9ad8\u905488.9%\uff0cMRD\u9670\u6027\u7387\u905466.7%\uff088\/12\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\uff0c93.3%\u7684\u60a3\u5152\uff0814\/15\uff0c\u7b2c2\u9031\u671f\u7b2c28\u5929\uff09\u7372\u5f97MMR\u53ca\u66f4\u6df1\u5206\u5b50\u7de9\u89e3\uff1b\u5169\u85e5\u5747\u53ef\u900f\u904e\u8840\u8166\u5c4f\u969c\uff0c\u5c0dABL1\u7a81\u8b8a\u60a3\u8005\u5747\u6709\u6548\uff0c\u5b89\u5168\u6027\u53ef\u63a7\u4e14\u7121\u6cbb\u7642\u76f8\u95dc\u6b7b\u4ea1\u3002\u8a72\u7814\u7a76\u8b49\u660e\uff0c\u8a72\u7121\u5316\u7642\u53e3\u670d\u96d9\u9776\u5411\u65b9\u6848\u53ef\u5e36\u4f86\u5feb\u901f\u3001\u6df1\u5ea6\u7de9\u89e3\uff0c\u70ba\u5152\u7ae5R\/R Ph+ ALL\u63d0\u4f9b\u5168\u65b0\u6cbb\u7642\u9078\u64c7\u3002 REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY \u4e00\u9805\u591a\u4e2d\u5fc3\u7814\u7a76\uff1a\u5229\u6c99\u6258\u514b\u62c9\u7528\u65bc\u9ad3\u7cfb\u816b\u7624\u7684\u771f\u5be6\u4e16\u754c\u7642\u6548\u8207\u5b89\u5168\u6027 \u6458\u8981\u7de8\u865f\uff1aEHA-5454 (PF562) \u7b2c\u4e00\u4f5c\u8005\uff1a\u66f9\u6668\uff0c\u5c71\u6771\u5927\u5b78\u9f4a\u9b6f\u91ab\u9662 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u570b\u5167\u591a\u4e2d\u5fc3\u771f\u5be6\u4e16\u754c\u7814\u7a76\uff08\u56de\u9867\u6027\uff09\uff0c\u65e8\u5728\u8a55\u4f30\u65b0\u578bBcl-2\u6291\u5236\u5291\u5229\u6c99\u6258\u514b\u62c9\u5728\u9ad3\u7cfb\u816b\u7624\u4e2d\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\u3002\u5171\u7d0d\u516530\u4f8b\u60a3\u8005\uff08\u4e2d\u4f4d\u5e74\u9f61\u70ba63\u6b72\uff09\uff0c\u5176\u4e2d\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff0925\u4f8b\uff0883%\uff09\u3001\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff093\u4f8b\uff0810%\uff09\u3001\u6162\u6027\u7c92\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\uff08CMML\uff092\u4f8b\uff087%\uff09\u3002AML\u60a3\u8005CR\/CRi\u9ad8\u905472%\uff0c\u5176\u4e2dELN\u4f4e\u5371\u7d44\u7642\u6548\u6700\u4f73\uff0887%\uff09\uff0c\u9996\u6b21\u9054\u5230CR\/CRi\u7684\u60a3\u8005\u4e2dMRD\u9670\u6027\u7387\u905461%\u3002NPM1\u7a81\u8b8a\u60a3\u8005CR\/CRi\u7387\u70ba100%\uff0cIDH2 \u7a81\u8b8a\u60a3\u8005\u70ba83%\u30023\u4f8bMDS\u60a3\u8005\u4e2d\uff0c2\u4f8b\u9054\u5230CRi\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u22653\u7d1a\u6cbb\u7642\u671f\u9593\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u4e3b\u8981\u70ba\u8840\u7d30\u80de\u6e1b\u5c11\uff08\u8840\u5c0f\u677f\u6e1b\u5c1127%\uff0c\u8ca7\u884023%\uff0c\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c1120%\uff09\uff0c\u6574\u9ad4\u53ef\u63a7\u3002\u8a72\u7814\u7a76\u8868\u660e\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728\u771f\u5be6\u4e16\u754c\u4e2d\u6cbb\u7642\u9ad3\u7cfb\u816b\u7624\uff08\u7279\u5225\u662fAML\uff09\u5177\u6709\u512a\u7570\u7684\u7642\u6548\u548c\u53ef\u63a7\u7684\u5b89\u5168\u6027\u3002 CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY \u4e00\u9805\u95dc\u9375II\u671f\u81e8\u5e8a\u7814\u7a76\u4e2d\u5229\u6c99\u6258\u514b\u62c9\uff08APG-2575\uff09\u6cbb\u7642\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u76f8\u95dc\u6027 \u6458\u8981\u7de8\u865f\uff1aEHA-3984 (PS1713) \u7b2c\u4e00\u4f5c\u8005\uff1a\u5468\u53ef\u6a39\u6559\u6388\uff0c\u6cb3\u5357\u7701\u816b\u7624\u91ab\u9662 \u95dc\u9375\u4fe1\u606f\uff1a\u9019\u662f\u4e00\u9805\u57fa\u65bc\u95dc\u9375II\u671f\u7814\u7a76NCT05147467\u7684\u76f8\u95dc\u6027\u5206\u6790\uff0c\u65e8\u5728\u63a2\u7d22\u5229\u6c99\u6258\u514b\u62c9\u6cbb\u7642R\/R CLL\/SLL\u60a3\u8005\u6642\u57fa\u7dda\u7279\u5fb5\u8207\u9810\u5f8c\u7684\u95dc\u4fc2\u3002\u7814\u7a76\u7d0d\u516577\u4f8b\u65e2\u5f80BTKi\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\uff0c\u63a5\u53d7\u5229\u6c99\u6258\u514b\u62c9600mg\u6bcf\u65e5\u4e00\u6b21\u6cbb\u7642\u3002\u572872\u4f8b\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dPFS\u70ba23.9\u500b\u6708\uff0cIRC\u8a55\u4f30ORR\u70ba62.5%\u3002\u9032\u4e00\u6b65\u5206\u6790\u986f\u793a\uff0cTP53\u7a81\u8b8a\/del(17p)\u3001\u8907\u96dc\u6838\u578b\u3001\u57fa\u6578\u8f03\u5927\u7684\u816b\u7624\u75c5\u7076\u53caSF3B1\u3001KIT\u3001BLM\u3001SETD2\u7a81\u8b8a\u8207\u8f03\u5dee\u9810\u5f8c\u76f8\u95dc\uff0c\u5176\u4e2d\u8907\u96dc\u6838\u578b\u548c\u816b\u7624\u5927\u5c0f\u662fPFS\u7e2e\u77ed\u7684\u7368\u7acb\u98a8\u96aa\u56e0\u7d20\u3002\u8a72\u7814\u7a76\u63d0\u793a\uff0c\u5229\u6c99\u6258\u514b\u62c9\u5728BTKi\u6cbb\u7642\u5931\u6557\u5f8c\u7684R\/R CLL\/SLL\u60a3\u8005\u4e2d\u5177\u6709\u660e\u78ba\u7642\u6548\uff0c\u4e26\u53ef\u901a\u904e\u57fa\u7dda\u98a8\u96aa\u7279\u5fb5\u9032\u4e00\u6b65\u8b58\u5225\u9810\u5f8c\u8f03\u5dee\u4eba\u7fa4\uff0c\u70ba\u5f8c\u7e8c\u98a8\u96aa\u5206\u5c64\u548c\u806f\u5408\u6cbb\u7642\u7b56\u7565\u63d0\u4f9b\u4f9d\u64da\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u3001\u751f\u7522\u548c\u5546\u696d\u5316\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\u3001\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u4ee5\u53ca\u86cb\u767d\u964d\u89e3\u5291\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u6cbb\u7642\u4f34\u6709T315I\u7a81\u8b8a\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u548c\u52a0\u901f\u671f\uff08CML-AP\uff09\u60a3\u8005\uff0c\u4ee5\u53ca\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u6210\u5e74\u60a3\u8005\u3002\u8a72\u85e5\u7269\u6240\u6709\u7372\u6279\u9069\u61c9\u75c7\u5747\u5df2\u88ab\u7d0d\u5165\u4e2d\u570b\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff08NRDL\uff09\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e09\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005POLARIS-1\u7814\u7a76\uff1b\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u7d93\u6cbbCML-CP\u6210\u5e74\u60a3\u8005\u7684POLARIS-2\u7814\u7a76\uff1b\u8a55\u4f30\u8010\u7acb\u514b\u00ae\u6cbb\u7642SDH-\u7f3a\u9677\u578bGIST\u60a3\u8005\u7684POLARIS-3\u7814\u7a76\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e00\u6b3e\u7528\u65bc\u6cbb\u7642\u591a\u7a2e\u8840\u6db2\u7cfb\u7d71\u60e1\u6027\u816b\u7624\u7684\u65b0\u578bBcl-2\u6291\u5236\u5291\u3002\u5229\u751f\u59a5\u00ae\u5df2\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\uff08NMPA\uff09\u6279\u51c6\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e\u4e00\u7a2e\u5305\u62ec\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u8a3b\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\uff1a\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u806f\u5408BTK\u6291\u5236\u5291\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7BTK\u6291\u5236\u5291\u6cbb\u7642\u8d85\u904e12\u500b\u6708\u4e14\u61c9\u7b54\u4e0d\u4f73\u7684CLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u4e0d\u8010\u53d7\u7684AML\u60a3\u8005\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u548c\u6b50\u6d32EMA\u8a31\u53ef\u7684\u8a55\u4f30\u5229\u751f\u59a5\u00ae\u4e00\u7dda\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371MDS\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u963f\u65af\u5229\u5eb7\u3001\u9ed8\u6c99\u6771\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u773e\u591a\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\u9054\u6210\u5168\u7403\u5408\u4f5c\uff0c\u540c\u6642\u8207\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u5efa\u7acb\u7814\u767c\u5408\u4f5c\u95dc\u4fc2\u3002\u5982\u9700\u77ad\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u8acb\u8a2a\u554f\u00a0https:\/\/ascentage.com\/ \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2026\u5e744\u670829\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u622a\u6b622025\u5e7412\u670831\u65e5\u7684\u5e74\u5ea6\u5831\u544a\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u8072\u660e\u7684\u8b66\u793a\u8072\u660e\u300d\u7ae0\u7bc0\uff0c2019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=445316#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=445316"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=445316#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-3.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/06\/Ascentage_APAC_Logo-3.jpg","width":399,"height":150},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=445316#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u3010EHA2026\u3011\u4e9e\u76db\u91ab\u85e5\u591a\u9805\u81e8\u5e8a\u6578\u64da\u4eae\u76f8\uff0c\u5f70\u986f\u8840\u6db2\u816b\u7624\u9818\u57df\u5168\u7403\u5275\u65b0\u5be6\u529b"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/445316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=445316"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/445316\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/445317"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=445316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=445316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=445316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}